0000950170-22-005253 | 10-K | XBRL Viewer

Print Document View Excel Document

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Aug. 31, 2020 USD ($) Installment shares	Dec. 31, 2021 USD ($) Installment shares	Dec. 31, 2020 USD ($)	Dec. 31, 2010 USD ($) Program	Jun. 15, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,070,000	$ 2,280,000
Change in fair value of contingent consideration		(210,000)
Milestones payments yet to be achieved		2,000,000.0	2,000,000.0
Milestones payment		0	0
Accounts Payable and Accrued Expenses [Member]
Commitments And Contingencies [Line Items]
Royalties due to both related and unrelated parties on accrued		$ 115,000	356,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability				$ 3,000,000.0	$ 5,000,000.0
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased \| Program				3
Number of development programs \| Program				6
Other noncurrent liability			$ 2,000,000.0
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years
Remaining amount paid in multiple installments	$ 280,000	$ 280,000
Number of installment become due within 12 months as full amount contingent consideration included in other noncurrent liabilities \| Installment		0
Change in fair value of contingent consideration		$ (210,000)
Industrial Seed Innovations [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable \| Installment	2	2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15.00%
Maximum [Member] \| Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626	132,626

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Average Estimated Useful Lives of Assets

Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:


	Years
Laboratory equipment	5
Software and computer equipment	3
Machinery and equipment	2-20
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

* Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net

Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands):


	Year Ended December 31,
	2021		2020
	(in thousands)
Research and development	$	98	$	341
Selling, general and administrative		1,443		1,701
Total stock-based compensation	$	1,541	$	2,042

Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):


	As of December 31,
	2021		2020
Customer B		11		21
Customer D		15		—
Customer C		—		12
Customer E		11		—
Customer A		—		57

Customers representing greater than 10% of total revenues were as follows (in percentages):


	For Year Ended December 31,
	2021		2020
Customer D		11		—
Customer B		10		7
Customer A		—		83

Inventory

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Inventory

Note 4. Inventory

Inventories, net consist of the following (in thousands):


	December 31, 2021		December 31, 2020
Raw materials	$	1,851	$	966
Goods in process		842		1,921
Finished goods		4,234		4,410
Inventories	$	6,927	$	7,297

The write-downs to inventory are included in cost of product revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. Therefore, if there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase our expenses in the period the write down is taken and materially affect our operating results. The Company recorded write-downs of wheat inventories, hemp seed inventories, and body care products of $3.6 million for the year ended December 31, 2021. The Company recorded $4.3 million of inventory write-downs for the year ended December 31, 2020.

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,134,000)	$ (6,026,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	(8,946,000)	(6,570,000)
Change in fair value of contingent consideration	(210,000)
Offering costs	769,000
Depreciation	929,000	632,000
Amortization of intangible assets	116,000	30,000
Lease amortization	1,276,000	1,048,000
Impairment of intangible asset	3,302,000	0
Impairment of goodwill	1,648,000	0
Loss (Gain) on disposal of equipment	23,000	(8,000)
Loss on disposal of intangible assets	222,000
Net amortization of investment premium		(44,000)
Stock-based compensation	1,541,000	2,042,000
Bed debt expense	76,000
Gain on sale of Verdeca		(8,814,000)
Realized gain on corporate securities	(10,221,000)
Corporate securities received in exchange for license agreement		(4,318,000)
Unrealized gain on corporate securities		(656,000)
Write-down of inventory and prepaid production costs	3,593,000	4,311,000
Loss on extinguishment of warrant liability		635,000
Gain on extinguishment of PPP loan	(1,123,000)
Impairment of property and equipment	1,534,000
Deferred income taxes		(107,000)
Changes in operating assets and liabilities:
Accounts receivable	(40,000)	(1,119,000)
Inventories	(2,383,000)	(9,751,000)
Prepaid expenses and other current assets	56,000	39,000
Other noncurrent assets	(158,000)	(15,000)
Accounts payable and accrued expenses	(372,000)	(580,000)
Amounts due to related parties	(16,000)	40,000
Unearned revenue	(8,000)	(34,000)
Other current liabilities	1,000	(43,000)
Operating lease payments	(1,343,000)	(910,000)
Net cash used in operating activities	(25,868,000)	(30,218,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	19,000	8,000
Purchases of property and equipment	(1,007,000)	(2,335,000)
Proceeds from sale of Verdeca		3,153,000
Acquisitions, net of cash acquired	(4,250,000)	(500,000)
Purchases of investments		(1,292,000)
Proceeds from sales and maturities of investments	21,846,000	18,250,000
Net cash provided by (used in) investing activities	16,608,000	17,284,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings		3,108,000
Payments of transaction costs relating to extinguishment of warrant liability		(863,000)
Principal payments on notes payable	(2,146,000)	(34,000)
Proceeds from exercise of warrants	22,000	9,372,000
Proceeds from exercise of stock options and purchases through ESPP	39,000	51,000
Capital contributions received from non-controlling interest	750,000	1,578,000
Net cash provided by financing activities	21,900,000	20,560,000
Effects of foreign currency translation on cash and cash equivalents	2,000
Net increase (decrease) in cash, cash equivalents and restricted cash	12,642,000	7,626,000
Cash, cash equivalents and restricted cash — beginning of period	16,043,000	8,417,000
Cash, cash equivalents and restricted cash — end of period	28,685,000	16,043,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	25,000	10,000
Cash paid for taxes	1,000	1,000
NONCASH TRANSACTIONS:
Right of use assets obtained in exchange for new operating lease liabilities	1,664,000	331,000
Right of use assets obtained through modification of existing lease agreement		4,207,000
Fixed assets acquired with notes payable		37,000
Purchases of fixed assets included in accounts payable and accrued expenses		71,000
Arcadia Wellness [Member]
NONCASH TRANSACTIONS:
Shares of common stock issued at closing of ISI transaction	2,053,000
Industrial Seed Innovations [Member]
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of contingent consideration	(210,000)
NONCASH TRANSACTIONS:
Shares of common stock issued at closing of ISI transaction		432,000
December 2020 Purchase Agreement [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement		287,000
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Offering	25,147,000
Payments of offering costs	(1,912,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement	$ 942,000
December 2020 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Offering		8,000,000
Payments of offering costs		(652,000)
May 2020 Warrants Transaction [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs		215,000
July 2020 Warrants Transaction [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs		$ 101,000

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 20. Income Taxes

The components of loss before income taxes are as follows (in thousands):


	Year Ended December 31,
	2021			2020
Domestic	$	(16,006	)	$	(6,150	)
Foreign		(126	)		—
Loss before income taxes	$	(16,132	)	$	(6,150	)

The total income tax (expense) benefit for the years ended December 31, 2021 and 2020 was $(2,000) and $124,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands):


	Year Ended December 31,
	2021			2020
Current:
Federal	$	—		$	—
State		(2	)		28
Foreign		—			(10	)
Total current tax (expense) benefit		(2	)		18
Deferred:
Federal		—			84
State		—			22
Foreign		—			—
Total deferred tax (expense) benefit		—			106
Total tax (expense) benefit	$	(2	)	$	124

The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:


	Year Ended December 31,
	2021			2020
Expected income tax provision at the federal statutory rate		21.0	%		21.0	%
State taxes, net of federal benefits		(20.1	)%		9.4	%
Impact of section 382 study		(10.4	)%		—
Change in valuation allowance		(0.4	)%		(43.8	)%
Transaction costs		(1.0	)%		(2.2	)%
Derivative liabilities		11.7	%		22.4	%
Non-Controlling Interest		(1.9	)%		(4.7	)%
Gain on debt extinguishment		1.5	%		—
withholding taxes		—			(0.2	)%
Other		(0.4	)%		—
Income tax provision		—			1.9	%

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):


	As of December 31,
	2021			2020
Deferred tax assets:
Net operating loss carryforwards	$	14,586		$	15,478
Unearned revenue		1			2
Stock-based compensation		3,677			3,881
Accrued payroll and benefits		3			236
Research and development credits		16			16
Fixed asset basis difference		73			84
Inventory reserve		422			491
Charitable contributions		2			3
Income from partnerships		163			—
Lease liability		752			1,622
Contingent consideration		456			531
Allowance for bad debt		27			—
Amortized intangibles		660			—
Goodwill		366			—
Total deferred tax assets		21,204			22,344
Deferred tax liabilities:
Right of use asset		(699	)		(1,548	)
Amortizable intangibles		—			(98	)
Income from partnerships		—			(13	)
Other		—			(174	)
Total deferred tax liabilities		(699	)		(1,833	)
Less valuation allowance		(20,505	)		(20,511	)
Net deferred tax assets	$	—		$	—

Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance decreased by $6,000 during the year ended December 31, 2021 and increased by $1.9 million during the year ended December 31, 2020.

At December 31, 2021, the Company had federal and state NOLs aggregating approximately $64.2 million and $23.9 million, respectively. At December 31, 2021, the utilization of a portion of the federal NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $208.1 million of federal NOLs available, approximately $144.0 million are expected to expire utilized due to ownership changes as defined in IRC Section 382. The Company is currently conducting additional analysis regarding the valuation of the Company at the time of the ownership changes to assess what, if any, portion of the $144.0 million limitation may be restored, but the NOL deferred tax asset as recorded currently reflects the full limitation. If not utilized, the federal and state NOLs will begin to expire in 2022 and 2024, respectively. IRC Section 382 may also limit NOLs generated in future years. The Company is currently conducting additional analysis regarding the valuation of the Company at the time of the ownership change to assess what, if any, portion of the limitation may be reversed. The Company’s ownership shift analysis was performed through December 31, 2021.

The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss

incurred through the year ended December 31, 2021. Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, for Federal tax losses before 2018 and for all state tax losses, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. Federal tax losses generated in 2018 and later do not expire. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2021, the Company’s tax years for 2002 through 2021 are generally subject to examination by the tax authorities. The years are open back to 2002 to the extent the NOLs being carried forward were generated then.

As of December 31, 2021, the Company had the following unrecognized tax benefits (in thousands):


	Year Ended December 31,
	2021		2020
Unrecognized tax benefit beginning balance	$	17	$	—
Increases for tax positions taken in prior years		—		2
Decreases for tax positions taken in prior years		—		—
Increases for tax positions taken in current years		—		15
Settlements		—		—
Unrecognized tax benefit ending balance	$	17	$	17

The Company is currently not under audit for federal or state purposes. The Company does not anticipate its total unrecognized tax benefits as of December 31, 2021 will significantly change due to settlement of examination or the expiration of statute of limitations during the next 12 months. The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals or other material deviation in this estimate over the next 12 months.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Investments and Fair Value Instruments (Tables)

12 Months Ended

Dec. 31, 2021

Investments And Fair Value Instruments [Abstract]

Summary of Amortized Cost and Fair Value of Investment Securities Portfolio


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2021
Cash equivalents:
Money market funds	$	26,842	$	—	$	—	$	26,842
Total Assets at Fair Value	$	26,842	$	—	$	—	$	26,842


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2020
Cash equivalents:
Money market funds	$	12,082	$	—	$	—	$	12,082
Short-term investments:
Corporate securities		10,969		656		—		11,625
Total Assets at Fair Value	$	23,051	$	656	$	—	$	23,707

Summary of Fair Value of Investment Securities

The fair value of the investment securities at December 31, 2021 were as follows:


	Fair Value Measurements at December 31, 2021
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	26,842	$	—	$	—	$	26,842
Total Assets at Fair Value	$	26,842	$	—	$	—	$	26,842

The fair value of the investment securities at December 31, 2020 were as follows:


	Fair Value Measurements at December 31, 2020
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,082	$	—	$	—	$	12,082
Short-term investments:
Corporate securities		11,625		—		—		11,625
Total Assets at Fair Value	$	23,707	$	—	$	—	$	23,707

Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model

The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2021 and 2020:


	January 2021 Warrants					September 2019 Warrants						June 2019 Warrants						March 2018 Warrants
	December 31, 2021			December 31, 2020		December 31, 2021			December 31, 2020			December 31, 2021			December 31, 2020			December 31, 2021			December 31, 2020
Expected term (in years)		4.58			—		3.20			4.20			2.96			3.96			1.22			2.22
Expected volatility		129.8	%		—		109.7	%		135.0	%		110.8	%		135.0	%		86.0	%		130.0	%
Risk-free interest rate		1.2	%		—		0.9	%		0.3	%		0.8	%		0.3	%		0.5	%		0.1	%
Expected dividend yield		0	%		—		0	%		0	%		0	%		0	%		0	%		0	%

Summary of Changes in Fair Value and Other Adjustments of Liabilities

The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):


(Dollars in thousands)	Common Stock Warrant Liability - March 2018 Purchase Agreement			Common Stock Warrant Liability - June 2018 Offering			Common Stock Warrant Liability - June 2019 Offering			Common Stock Warrant Liability - September 2019 Offering			Common Stock Warrant Liability - January 2021 Offering			Contingent Liabilities			Total
Balance as of December 31, 2019	$	4,579		$	5,444		$	1,993		$	2,920		$	—		$	2,000		$	16,936
Change in fair value and other adjustments		(2,277	)		(1,426	)		(1,161	)		(1,706	)		—			—		$	(6,570	)
Exercise of warrants		(1,641	)		(4,018	)		—			—			—			—		$	(5,659	)
ISI acquisition contingent consideration		—			—			—			—			—			280		$	280
Balance as of December 31, 2020	$	661		$	—		$	832		$	1,214		$	—		$	2,280		$	4,987
Initial recognition		—			—			—			—		$	9,631			—		$	9,631
Change in fair value and other adjustments		(654	)		—			(662	)		(991	)		(6,638	)		(210	)	$	(9,155	)
Balance as of December 31, 2021	$	7		$	—		$	170		$	223		$	2,993		$	2,070		$	5,463

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Arcadia Wellness Acquisition - Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Weighted average shares - Basic and diluted	21,280,620	9,959,018
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Total revenues	$ 9,062	$ 14,684
Net loss	(17,854)	(8,152)
Net loss attributable to common stockholders	$ (16,380)	$ (6,781)
Weighted average shares - Basic and diluted	21,590,895	10,786,418
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.76)	$ (0.63)

Arcadia Wellness Acquisition - Schedule of Preliminary Allocation of the Purchase Price of Assets Acquired Based on Fair Values (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	May 17, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 408
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Inventory	$ 840
Prepaid and other current assets	62
Fixed assets	308
Deposits	82
Customer list	360
Trade names and trademarks	2,900
Formulations	260
Goodwill	1,240	$ 1,200
Total consideration allocated	$ 6,052

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of the Company, Arcadia Wellness, Arcadia Spain and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission.

The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.

For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $1,474,000 and $1,371,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2021 and 2020, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2021 and 2020.

The functional currency of the foreign subsidiary Arcadia Spain during the year ended December 31, 2021, was its local currency (i.e., the Euro). Accordingly, period-end exchange rates were applied to translate its assets and liabilities and average transaction exchange rates to translate its revenues, expenses, gains, and losses into U.S. dollars. Upon disposal of all of the assets and liabilities related to Arcadia Spain, the Company deconsolidated the accounts of the subsidiary as of November 30, 2021, and recorded a loss on the sale in the amount of $497,000 during the quarter ended December 31, 2021.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, impairments of long-lived assets such as intangible assets and goodwill, impairment of property and equipment, and net realizable value of inventory. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and cash equivalents

The Company considers any liquid investment with a stated maturity of three months or less at the date of purchase to be a cash equivalent. Cash and cash equivalents consist of cash on deposit with banks, and money-market funds. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2021 and 2020, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.

Restricted cash

Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the consolidated balance sheets.

Investments in debt and equity securities

Investments in debt and equity securities are carried at fair value and classified as short-term investments. Realized and unrealized gains and losses on investment securities are included in other income, net, in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date.

Other-than-temporary impairments on investments

The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2021, the Company had no short-term investments, and as of December 31, 2020, there was no impairment of the Company’s investments.

Accounts receivable

Accounts receivable represents amounts owed to the Company from product sales, licenses, and royalties. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had $76,000 and $0 amounts reserved for doubtful accounts at December 31, 2021 and 2020, respectively, and the allowance activity during the year ended December 31, 2021, was immaterial.

Inventory

Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value.

GoodWheat: Proprietary wheat plants are grown, producing seed and grain with a variety of improved nutritional qualities, including high levels of amylose, improved shelf-life, and reduced gluten. The seed is used for subsequent plantings and the grain is either sold or used as an ingredient in the production of food products, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process harvested seed and grain, and costs to mill the grain into flour.

Body care: A portfolio of CBD-infused and CBD-free consumer bath and body care products such as body lotions, bath-bombs and topical pain relievers, that are produced in the US. Amounts inventoried consist primarily of purchased raw materials, components, labor, and manufacturing facility costs.

Zola Coconut water: Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor.

GoodHemp: Proprietary seeds are grown and used for subsequent plantings and sold as final product to other growers. Amounts in inventory for internally produced hemp seeds consist primarily of labor, supplies and facility costs. The costs to procure seeds from external growers and suppliers are included in inventory, as well. In addition, hemp seeds were planted on land leased in Hawaii. The costs of purchasing, planting and growing the seed, and harvesting the resulting biomass are captured as inventory, along with the costs to process the biomass into CBD oil. Amounts in inventory for growing biomass primarily consist of labor, supplies and facility costs.

The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat seed and grain, body care products, Zola Coconut water, and hemp seed. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain, and GoodHemp seed.

Raw materials inventories consist primarily of the costs to produce body care products and GoodWheat seeds. Goods in process inventories consist of costs to produce GoodHemp seed, hemp seed production costs incurred by Archipelago, and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat and body care products, and GoodHemp seeds that are available for sale.

Property and equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:


	Years
Laboratory equipment	5
Software and computer equipment	3
Machinery and equipment	2-20
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

* Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of fixed assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value.

Impairment of long-lived intangible assets and goodwill

The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value.

Intangible assets, net

As of December 31, 2021 and 2020, there were $3.3 million and $0, respectively of impairment of intangible assets, recorded on the consolidated statements of operations and comprehensive loss. See Note 9 for more information.

Goodwill

During the year ended December 31, 2021, the Company recorded an impairment charge of $1.6 million, which was included as impairment of goodwill on our consolidated statements of operations and comprehensive loss. The goodwill carrying value of $1.6 million was fully impaired. See Note 7 and 8 for the goodwill recorded at the time of the ISI and AW acquisitions, respectively. The impairment charge was primarily the result of weakness in our newly acquired consumer product margins combined with a volatile economic climate and higher than normal inflation. The decline in the stock price observed during the fourth quarter of 2021, pushed our market capitalization significantly below the recorded value of our stockholders' equity. No goodwill impairment charges were recorded during the year ended December 31, 2020.

Fair value of financial instruments

Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 inputs are unobservable inputs for the asset or liability.

The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable approximated their fair values due to the short period of time to maturity or repayment.

Concentration of risk

Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.

Customer concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):


	As of December 31,
	2021		2020
Customer B		11		21
Customer D		15		—
Customer C		—		12
Customer E		11		—
Customer A		—		57

Customers representing greater than 10% of total revenues were as follows (in percentages):


	For Year Ended December 31,
	2021		2020
Customer D		11		—
Customer B		10		7
Customer A		—		83

Stock-based compensation

The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 16 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands):


	Year Ended December 31,
	2021		2020
	(in thousands)
Research and development	$	98	$	341
Selling, general and administrative		1,443		1,701
Total stock-based compensation	$	1,541	$	2,042

Income taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

Net loss per share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.

Revenue recognition

The Company derives its revenues from product sales, licensing agreements, royalty fees, contract research agreements, and government grants.

Product revenues

Product revenues to date have consisted primarily of sales of SONOVA GLA products, GoodWheat grain sales, body care products, Zola Coconut water, and GoodHemp seed sales. The Company recognizes revenue from product sales when ownership of the product is transferred to third-party distributors and consumers, collectively “our customers”, which generally occurs upon delivery. Shipping and handling costs charged to customers are

recorded as revenues and included in cost of product revenues at the time the sale is recognized. Revenues fluctuate depending on the timing of shipments of product to our customers.

License revenues

License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur.

Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees. Milestones typically consist of significant stages of development for the Company’s traits in a potential commercial product, such as achievement of specific technological targets, completion of field trials, filing with regulatory agencies, completion of the regulatory process, and commercial launch of a product containing the Company’s traits. Given the seasonality of agriculture and time required to progress from one milestone to the next, achievement of milestones is inherently uneven, and the Company’s license revenues are likely to fluctuate significantly from period to period.

Royalty revenues

Royalty revenues from the Company’s agreements with third parties are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee.

Contract research and government grant revenues

Contract research and government grant revenues consist of amounts earned from performing contracted research primarily related to breeding programs or the genetic engineering of plants for third parties. Contract research revenue and government grants revenues are accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g., costs incurred to date relative to the total estimated costs at completion). The Company receives payments from government entities in the form of government grants. The Company’s obligation with respect to these government agreements is to perform the research on a best-efforts basis.

Unearned revenue

The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies. During the year ended December 31, 2021, the Company recognized revenue of $8,000 that was included in unearned revenue on the consolidated balance sheet as of December 31, 2020.

Cost of product revenues

Cost of product revenues relates to the sale of GoodWheat, Zola Coconut water, body care, GLA oil and GoodHemp products and consists of manufacturing costs, including production overhead costs such as depreciation, rent and others, in-licensing and royalty fees, any adjustments or write-downs to inventory, as well as the cost of raw materials, including inventory and third-party services costs related to procuring, processing, formulating, packaging, and shipping the Company’s products.

Research and development expenses

Research and development expenses consist of costs incurred in the discovery, development, and testing of the Company’s products and products in development incorporating the Company’s traits. These expenses consist primarily of employee salaries and benefits, fees paid to subcontracted research providers, fees associated with in-licensing technology, land leased for field trials, chemicals and supplies, and other external expenses. These costs are expensed as incurred.

Change in fair value of contingent consideration

Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 17.

Change in the estimated fair value of common stock warrant liabilities

Change in the estimated fair value of common stock warrant liabilities is comprised of the fair value remeasurement of liability classified common stock warrants. See Note 15.

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2021
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and equipment [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Machinery and equipment [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	20 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842, Leases, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability.
Operating Lease, Liability	$ 3,294	$ 6,106
Right of use assets	$ 3,081	$ 5,826
Lease option to extend, description	Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Operating leases, term of contract	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years
Operating leases, term of contract	5 years
ASU 2016-02
Lessee Lease Description [Line Items]
Operating Lease, Liability	$ 2,800
Right of use assets	$ 2,600
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	5 years	5 years
Office Space [Member] \| Chesterfield, MO And Chatsworth, CA [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	35 months
Existence of option to extend	true

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	As of December 31,
	2021			2020
Laboratory equipment	$	2,659		$	2,951
Software and computer equipment		548			591
Machinery and equipment		1,809			2,046
Furniture and fixtures		211			181
Vehicles		417			428
Leasehold improvements		2,306			2,229
Property and equipment, gross		7,950			8,426
Less accumulated depreciation and amortization		(5,659	)		(4,887	)
Property and equipment, net	$	2,291		$	3,539

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Employer matching contribution, percent	50.00%
Maximum annual contribution per employee, percent	3.00%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):


	Year Ended December 31,
	2021		2020
Options to purchase common stock		1,422,195		889,759
Warrants to purchase common stock		11,510,011		7,200,280
Total		12,932,206		8,090,039

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee Disclosure [Abstract]
2022	$ 1,217
2023	1,237
2024	973
2025	168
Total operating lease payments	3,595
Less: imputed interest	301
Operating Lease Liability	$ 3,294	$ 6,106

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,851	$ 966
Goods in process	842	1,921
Finished goods	4,234	4,410
Inventories	$ 6,927	$ 7,297

Intangible Assets, Net

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

Note 9. Intangible assets, net

The Company’s intangible assets, net as of December 31, 2021 and 2020, consist of the following:


	December 31, 2021						December 31, 2020
	Gross Carrying Amount		Accumulated Amortization and Impairment (1)		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Amortized intangible assets
Intellectual property	$	570	$	419	$	151	$	310	$	27	$	283
Customer lists		400		355		45		40		3		37
Total amortizable intangible assets	$	970	$	774	$	196	$	350	$	30	$	320

Indefinite-lived intangible assets
Brands and trademarks	$	2,950	$	2,662	$	288	$	50	$	—	$	50
Total intangible asset, net	$	3,920	$	3,436	$	484	$	400	$	30	$	370

(1) During the year ended December 31, 2021, the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $3.3 million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

Intellectual property and customer lists will be amortized based on their useful lives ranging between 4 and 15 years. As of December 31, 2021, future amortization of intellectual property and customer lists is as follows:


Year Ending December 31,
2022	$	53
2023		53
2024		53
2025		4
2026		4
Thereafter		28
Total	$	196

Intangible Assets, Net - Schedule of Intangible Assets, Net (Detail) - USD ($)
$ in Thousands

Dec. 31, 2021

Dec. 31, 2020

Finite And Indefinite Lived Intangible Assets [Line Items]

Amortized intangible assets, Gross Carrying Amount

$ 970

$ 350

Amortized intangible assets, Accumulated Amortization and Impairment

774

^[1]

Finite-Lived Intangible Assets, Net, Total

196

320

Indefinite-lived intangible assets, Gross Carrying Amount

3,920

400

Indefinite Lived Intangible Assets Accumulated Amortization And Impairment

3,436

^[1]

Indefinite lived intangible assets, Net Carrying Amount

484

370

Brands and Trademarks [Member]

Finite And Indefinite Lived Intangible Assets [Line Items]

Indefinite-lived intangible assets, Gross Carrying Amount

2,950

Indefinite Lived Intangible Assets Accumulated Amortization And Impairment

^[1]

2,662

Indefinite lived intangible assets, Net Carrying Amount

288

Intellectual Property [Member]

Finite And Indefinite Lived Intangible Assets [Line Items]

Amortized intangible assets, Gross Carrying Amount

570

310

Amortized intangible assets, Accumulated Amortization and Impairment

419

^[1]

Finite-Lived Intangible Assets, Net, Total

151

283

Customer Lists [Member]

Finite And Indefinite Lived Intangible Assets [Line Items]

Amortized intangible assets, Gross Carrying Amount

400

Amortized intangible assets, Accumulated Amortization and Impairment

355

^[1]

Finite-Lived Intangible Assets, Net, Total

$ 45

$ 37

[1]

During the year ended December 31, 2021, the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of our acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $3.3 million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 28,685	$ 14,042
Short-term investments		11,625
Accounts receivable, net of allowance for doubtful accounts of $76 and $0 as of December 31, 2021 and 2020, respectively	1,370	1,406
Inventories, net — current	4,433	3,812
Prepaid expenses and other current assets	900	811
Total current assets	35,388	31,696
Restricted cash		2,001
Property and equipment, net	2,291	3,539
Right of use assets	3,081	5,826
Inventories, net — noncurrent	2,494	3,485
Goodwill		408
Intangible assets, net	484	370
Other noncurrent assets	180	23
Total assets	43,918	47,348
Current liabilities:
Accounts payable and accrued expenses	3,638	4,105
Amounts due to related parties	64	80
Debt - current	0	1,141
Unearned revenue — current		8
Operating lease liability - current	1,074	717
Other current liabilities	264	263
Total current liabilities	5,040	6,314
Debt - noncurrent	0	2,105
Operating lease liability - noncurrent	2,220	5,389
Common stock warrant liabilities	3,392	2,708
Other noncurrent liabilities	2,070	2,280
Total liabilities	12,722	18,796
Commitments and contingencies (Note 17)
Stockholders’ equity:
Common stock, $0.001 par value 150,000,000 shares authorized as of December 31, 2021 and December 31, 2020; 22,184,235 and 13,450,861 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively.	63	54
Additional paid-in capital	257,515	239,496
Accumulated deficit	(226,485)	(211,825)
Total Arcadia Biosciences stockholders’ equity	31,093	27,725
Non-controlling interest	103	827
Total stockholders' equity	31,196	28,552
Total liabilities and stockholders’ equity	$ 43,918	$ 47,348

Leases

12 Months Ended

Dec. 31, 2021

Lessee Disclosure [Abstract]

Leases

Note 18. Leases

Operating Leases

As of December 31, 2021, the Company leases office space in Davis, CA, Chatsworth, CA, and Chesterfield, MO, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to a third party. During the year ended December 31, 2021, the Company entered into two leases for office space in Chesterfield, MO, and for office space and

production in Chatsworth, CA, both with a lease term of 35 months following the commencement date and no renewal option. The leases commenced in April and May of 2021, respectively. There are no other leases that have not yet commenced as of December 31, 2021.

Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. During the year ended December 31, 2020, the Company entered into a lease amendment that provided for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The Company initially expected to exercise its options to renew, and in accordance with ASC 842, Leases, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability. During the year ended December 31, 2021, the Company re-assessed its long-term strategy regarding office spaces, and determined that the expectation to exercise its option to renew for an additional five-year term after April 2025 is no longer reasonable. In accordance with ASC 842, the Company accounted for the change that resulted in a decrease of $2.8 million for the operating lease liability and of $2.6 million for the right of use asset.

The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands):


Leases	Classification	December 31, 2021		December 31, 2020
Assets
Operating lease assets	Right of use asset	$	3,081	$	5,826
Total leased assets		$	3,081	$	5,826
Liabilities
Current - Operating	Operating lease liability - current	$	1,074	$	717
Noncurrent - Operating	Operating lease liability - noncurrent		2,220		5,389
Total leased liabilities		$	3,294	$	6,106


Lease Cost	Classification	For the Year Ended December 31, 2021			For the Year Ended December 31, 2020
Operating lease cost	SG&A and R&D Expenses	$	1,352		$	1,042
Short term lease cost (1)	SG&A and R&D Expenses		133			305
Sublease income (2)	SG&A and R&D Expenses		(63	)		(45	)
Net lease cost		$	1,422		$	1,302

(1)

Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less.

(2)

Sublease income is recorded as a reduction to lease expense.


Lease Term and Discount Rate	December 31, 2021			December 31, 2020
Weighted-average remaining lease term (years)		2.7			5.0
Weighted-average discount rate		6	%		6	%

The maturities of the operating lease liabilities as of December 31, 2021 are as follows (in thousands):


Years Ending December 31,	Amounts
2022	$	1,217
2023		1,237
2024		973
2025		168
2026 and thereafter		—
Total operating lease payments	$	3,595
Less: imputed interest	$	301
Total current and noncurrent operating lease liabilities	$	3,294

Net Loss per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Net Loss per Share

Note 23. Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the years ended December 31, 2021 and 2020, all potentially dilutive common shares were determined to be anti-dilutive.

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):


	Year Ended December 31,
	2021		2020
Options to purchase common stock		1,422,195		889,759
Warrants to purchase common stock		11,510,011		7,200,280
Total		12,932,206		8,090,039

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 76,000	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	22,184,235	13,450,861
Common stock, outstanding	22,184,235	13,450,861

Summary of Significant Accounting Policies - Schedule of Customers Representing Greater than 10% of Account Receivable and Total Revenue (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable [Member] \| Customer A
Concentration Risk [Line Items]
Concentration risk percentage		57.00%
Accounts Receivable [Member] \| Customer B
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	21.00%
Accounts Receivable [Member] \| Customer C
Concentration Risk [Line Items]
Concentration risk percentage		12.00%
Accounts Receivable [Member] \| Customer D
Concentration Risk [Line Items]
Concentration risk percentage	15.00%
Accounts Receivable [Member] \| Customer E
Concentration Risk [Line Items]
Concentration risk percentage	11.00%
Total Revenue [Member] \| Customer A
Concentration Risk [Line Items]
Concentration risk percentage		83.00%
Total Revenue [Member] \| Customer B
Concentration Risk [Line Items]
Concentration risk percentage	10.00%	7.00%
Total Revenue [Member] \| Customer D
Concentration Risk [Line Items]
Concentration risk percentage	11.00%

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Intangible Assets, Net - Additional Information (Detail) - Intellectual Property And Customer Lists [Member]	12 Months Ended
	Dec. 31, 2021
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	4 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	15 years

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 6,780	$ 8,034
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	6,003	761
Argentina
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	26	6,681
India
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	7	100
Africa
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues		106
Canada
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	503	354
Spain
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	225
United Kingdom
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 16
Austria
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues		$ 32

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 26,842	$ 23,051
Unrealized Gains		656
Estimated Fair Value	26,842	23,707
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	26,842	12,082
Estimated Fair Value	$ 26,842	12,082
Short-term Investments [Member] \| Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		10,969
Unrealized Gains		656
Estimated Fair Value		$ 11,625

Investments and Fair Value Instruments - Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Common Stock Warrant Liability [Member] - Level 3 [Member]	Dec. 31, 2021	Dec. 31, 2020
Expected Term [Member] \| January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	4 years 6 months 29 days
Expected Term [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	3 years 2 months 12 days	4 years 2 months 12 days
Expected Term [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	2 years 11 months 15 days	3 years 11 months 15 days
Expected Term [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	1 year 2 months 19 days	2 years 2 months 19 days
Expected Volatility [Member] \| January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	129.8
Expected Volatility [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	109.7	135.0
Expected Volatility [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	110.8	135.0
Expected Volatility [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	86.0	130.0
Risk-Free Interest Rate [Member] \| January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.2
Risk-Free Interest Rate [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.9	0.3
Risk-Free Interest Rate [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.8	0.3
Risk-Free Interest Rate [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.5	0.1
Expected Dividend Yield [Member] \| January 2021 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0
Expected Dividend Yield [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 6,780,000	$ 8,034,000
Operating expenses (income):
Cost of product revenues	8,708,000	5,199,000
Research and development	3,889,000	7,960,000
Gain on sale of Verdeca		(8,814,000)
Loss on sale of Arcadia Spain	497,000
Impairment of intangible asset	3,302,000	0
Impairment of goodwill	1,648,000	0
Change in fair value of contingent consideration	(210,000)
Impairment of property and equipment, net	1,534,000	0
Selling, general and administrative	22,938,000	16,467,000
Total operating expenses	42,306,000	20,812,000
Loss from operations	(35,526,000)	(12,778,000)
Interest expense	(20,000)	(47,000)
Other income, net	10,114,000	740,000
Change in fair value of common stock warrant liabilities	8,946,000	6,570,000
Loss on extinguishment of warrant liability		(635,000)
Gain on extinguishment of PPP loan	1,123,000
Offering costs	(769,000)
Net loss before income taxes	(16,132,000)	(6,150,000)
Income tax (provision) benefit	(2,000)	124,000
Net loss	(16,134,000)	(6,026,000)
Net loss attributable to non-controlling interest	(1,474,000)	(1,371,000)
Net loss attributable to common stockholders	$ (14,660,000)	$ (4,655,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.69)	$ (0.47)
Weighted-average number of shares used in per share calculations:
Basic and diluted	21,280,620	9,959,018
Other comprehensive loss, net of tax
Unrealized losses on investment securities		$ (1,000)
Other comprehensive loss		(1,000)
Comprehensive loss attributable to common stockholders	$ (14,660,000)	(4,656,000)
Product
Revenues:
Total revenues	6,587,000	1,044,000
License
Revenues:
Total revenues	17,000	6,801,000
Royalty
Revenues:
Total revenues	$ 176,000	83,000
Contract Research And Government Grants
Revenues:
Total revenues		$ 106,000

Arcadia Wellness Acquisition - Additional Information (Detail) - USD ($)			7 Months Ended	12 Months Ended
	May 31, 2021	May 17, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Lease option to extend, description				Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Total revenues				$ 6,780,000	$ 8,034,000
Net income attributable to common stockholders				$ (14,660,000)	(4,655,000)
Goodwill					$ 408,000
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 6,100,000
Cash paid for Acquisition	4,000.0
Business combination, equity interest issuable, value	$ 2,100
Operating leases, term of contract			3 years	3 years
Lease option to extend, description				The lease was effective on May 17, 2021 and has a term of 3 years.
Total revenues			$ 4,300,000
Net income attributable to common stockholders			7,500,000
Intangible assets, net		$ 3,500,000
Weighted average useful life		12 years 10 months 24 days
Goodwill		$ 1,200,000	$ 1,240,000	$ 1,240,000
Arcadia Wellness [Member] \| Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets, net		2,900,000
Arcadia Wellness [Member] \| Customer List [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 360,000
Useful life		15 years
Arcadia Wellness [Member] \| Formulations [Member]
Business Acquisition [Line Items]
Intangible assets, net		$ 260,000
Useful life		10 years
Arcadia Wellness [Member] \| Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs				$ 850,000
Arcadia Wellness [Member] \| Common Stock [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares	827,401

Warrants

12 Months Ended

Dec. 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrants

Note 15. Warrants

Common Stock Warrant transactions

In July 2020, an existing accredited investor exercised its March 2018 Warrants (the “July 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 641,416 shares of the Company’s common stock at a reduced exercise price of $3.975 per share for gross proceeds of $2.6 million. As consideration for the exercise of these March 2018 Warrants, the Company issued new unregistered warrants to purchase up to 641,416 shares of common stock (the “July 2020 Warrants”) at an exercise price of $3.85 per share with an exercise period of 5.5 years from the date of issuance. The July 2020 Warrants were valued at $2.1 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 126 percent, stock price of $3.73, and risk-free rate of 0.35%. In connection with the July 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 32,071 shares of common stock (the “July 2020 Placement Agent Warrants”) that have an exercise price per share equal to $4.969 and a term of 5.5 years. The value of the July 2020 Placement Agent Warrants was determined to be $101,000 using the Black-Scholes Model. The Company recognized a loss on extinguishment of warrant liability in the amount of $682,000 associated with this transaction, during the quarter ended September 30, 2020.

In May 2020, several existing accredited investors exercised the June 2018 Warrants (the “May 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 1,392,345 shares of the Company’s common stock at a reduced exercise price of $4.90 per share for gross proceeds of $6.8 million. As consideration for the exercise of the June 2018 Warrants, the Company issued new unregistered warrants to purchase up to 1,392,345 shares of common stock (the “May 2020 Warrants”) at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance. The May 2020 Warrants were valued at $4.4 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 128 percent, stock price of $3.81, and risk-free rate of 0.38%. In connection with the May 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (the “May 2020 Placement Agent Warrants”) that have an exercise price per share equal to $6.125 and a term of five years. The value of the May 2020 Placement Agent Warrants was determined to be $215,000 using the Black-Scholes Model. The Company recognized a gain on extinguishment of warrant liability in the amount of $47,000 associated with this transaction, during the quarter ended June 30, 2020.

Equity Classified Common Stock Warrants

In connection with professional services agreements with non-affiliated third parties, during the years ended December 31, 2021 and 2020, the Company issued service and performance warrants (“Service and Performance Warrants”).

As of December 31, 2021, the Company issued the following warrants to purchase shares of its common stock. These warrants are exercisable any time at the option of the holder until their expiration date.


	Issuance Date	Term	Exercise Price Per Share		Warrants Exercised during the Year Ended December 31, 2020		Warrants Outstanding at December 31, 2020		Warrants Exercised during the Year Ended December 31, 2021			Warrants Outstanding at December 31, 2021
January 2021 Placement Agent Warrants	January 2021	5.5 years	$	3.99		—		—		—			393,839
January 2021 Service and Performance Warrants	January 2021	2 years	$	3.08		—		—		—			7,500
December 2020 Warrants	December 2020	5.5 years	$	3.00		—		2,618,658		—			2,618,658
December 2020 Placement Agent Warrants	December 2020	5 years	$	3.82		—		130,933		—			130,933
July 2020 Warrants	July 2020	5.5 years	$	3.85		—		641,416		—			641,416
July 2020 Placement Agent Warrants	July 2020	5.5 years	$	4.97		—		32,071		—			32,071
May 2020 Warrants	May 2020	5 years	$	4.78		—		1,392,345		—			1,392,345
May 2020 Placement Agent Warrants	May 2020	5 years	$	6.13		—		69,617		—			69,617
March 2020 Service and Performance Warrants	March 2020	3 years	$	2.50		—		18,350		—			18,350
February 12, 2020 Service and Performance Warrants	February 2020	2 years	$	4.71		—		150,000		—			150,000
February 3, 2020 Service and Performance Warrants	February 2020	2 years	$	4.91		—		10,000		—			10,000
September 2019 Placement Agent Warrants	September 2019	5 years	$	9.48		—		65,942		—			65,942
August 2019 Service and Performance Warrants	August 2019	2 years	$	1.92		—		20,000		(20,000	)		—
July 2019 Service and Performance Warrants	July 2019	2 years	$	2.19		—		10,000		(10,000	)		—
June 2019 Placement Agent Warrants	June 2019	5 years	$	6.29		—		74,479		—			74,479
April 2019 Service and Performance Warrants	April 2019	5 years	$	6.18		—		145,154		—			145,154
June 2018 Placement Agent Warrants	June 2018	5 years	$	12.57		—		69,617		—			69,617
March 2018 Placement Agent Warrants	March 2018	5 years	$	41.56		—		15,038		—			15,038
Total						—		5,463,620		(30,000	)		5,834,959

Liability Classified Common Stock Warrants

Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the warrant liability is recorded as change in fair value of common stock warrant liabilities in the consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified common stock warrants are summarized as follows:


	Issuance Date	Term	Exercise Price Per Share		Warrants Exercised during the Year Ended December 31, 2020		Warrants Outstanding at December 31, 2020		Warrants Exercised during the Year Ended December 31, 2021		Warrants Outstanding at December 31, 2021
January 2021 Warrants	January 2021	5.5 years	$	3.13		—		—		—		3,938,392
September 2019 Warrants	September 2019	5.5 years	$	7.52		—		659,414		—		659,414
June 2019 Warrants	June 2019	5.5 years	$	5.00		—		435,830		—		435,830
June 2018 Warrants	June 2018	5.5 years	$	9.94		1,392,345		—		—		—
March 2018 Warrants	March 2018	5 years	$	10.73		641,416		641,416		—		641,416
Total						2,033,761		1,736,660		—		5,675,052

See Note 6 for the Black-Scholes option-pricing model and weighted-average assumptions used to estimate the fair value of the warrant liabilities.

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Line Items]
Net loss attributable to noncontrolling interest	$ 1,474,000	$ 1,371,000
Loss on disposal of foreign subsidiary	(497,000)
Reserved for doubtful accounts	76,000	0
Impairment of intangible asset	3,302,000	0
Impairment of goodwill	1,648,000	0
Revenue recognized	8,000
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Impairment of Short-Term Investments	$ 0
Impairment of equity method investments		$ 0

Warrants - Additional Information (Detail)	1 Months Ended		3 Months Ended		12 Months Ended
Warrants - Additional Information (Detail)	Jul. 31, 2020 USD ($) $ / shares shares	May 31, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares					(30,000)
Gross proceeds from warrants exercise \| $					$ 22,000	$ 9,372,000
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability \| $			$ 682,000
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares	$ 3.85
Warrant issued, shares of common stock called by warrant \| shares	641,416
Warrant, exercisable term	5 years 6 months
Value of warrants \| $	$ 2,100
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	1.26
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	3.73
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0.0035
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability \| $				$ 47,000
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares		$ 4.775
Warrant issued, shares of common stock called by warrant \| shares		1,392,345
Warrant, exercisable term		5 years
Value of warrants \| $		$ 4,400,000
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		1.28
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		3.81
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		0.0038
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares						641,416
Warrants issued, exercise price \| $ / shares					$ 10.73
March 2018 Warrants [Member] \| July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares	641,416
Warrants issued, exercise price \| $ / shares	$ 3.975
Gross proceeds from warrants exercise \| $	$ 2,600,000
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares						1,392,345
Warrants issued, exercise price \| $ / shares					$ 9.94
June 2018 Warrants [Member] \| May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares		1,392,345
Warrants issued, exercise price \| $ / shares		$ 4.90
Gross proceeds from warrants exercise \| $		$ 6,800,000
Placement Agent [Member] \| July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares	$ 4.969
Warrant issued, shares of common stock called by warrant \| shares	32,071
Warrant, exercisable term	5 years 6 months
Value of warrants \| $	$ 101,000
Placement Agent [Member] \| May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares		$ 6.125
Warrant issued, shares of common stock called by warrant \| shares		69,617
Warrant, exercisable term		5 years
Value of warrants \| $		$ 215,000

Stock-Based Compensation and Employee Stock Purchase Program (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Incentive Plans

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):


	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2019		661,701		$	21.60	$	305
Options granted		502,494			4.28		—
Options exercised		—			—		—
Options forfeited		(174,508	)		5.91		—
Options expired		(99,928	)		25.56		—
Outstanding — Balance at December 31, 2020		889,759			14.46	$	240
Options granted		1,227,042			2.76		—
Options exercised		—			—		—
Options forfeited		(440,166	)		3.09	$	1,086
Options expired		(254,440	)		29.02		—
Outstanding — Balance at December 31, 2021		1,422,195			5.28		—
Vested and expected to vest — December 31, 2021		1,322,111			5.47		—
Exercisable —December 31, 2021		743,109		$	7.54		—

Weighted-Average Fair Value Assumption of Stock Option Awards

The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:


	Year Ended December 31,
Assumptions	2021			2020
Expected term (years)		6.31			6.48
Expected volatility		121	%		134	%
Risk-free interest rate		0.86	%		1.01	%
Expected dividend yield		—			—

Property and Equipment, Net

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Note 5. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	As of December 31,
	2021			2020
Laboratory equipment	$	2,659		$	2,951
Software and computer equipment		548			591
Machinery and equipment		1,809			2,046
Furniture and fixtures		211			181
Vehicles		417			428
Leasehold improvements		2,306			2,229
Property and equipment, gross		7,950			8,426
Less accumulated depreciation and amortization		(5,659	)		(4,887	)
Property and equipment, net	$	2,291		$	3,539

Depreciation expense was $929,000 and $632,000 for the years ended December 31, 2021 and 2020, respectively.

As of December 31, 2021 and 2020, respectively, there was $267,000 and $239,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation.

The Company recorded impairments of property and equipment in the amount of $1.5 million and $0 for the years ended December 31, 2021, and 2020, respectively. The majority was related to the fact that Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. As a result, the Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, and recorded write-downs in the amount of $1.4 million for the year ended December 31, 2021, calculating the fair value using prices for similar assets. An additional fixed assets impairment in the amount of $100,000 was recorded as of December 31, 2021, for other fixed assets, not related to Archipelago, determined to have no future economic benefit.

Inventory - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Write-down of inventory	$ 3.6	$ 4.3

Investments and Fair Value Instruments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Realized gain on sale of investments	$ 10,200,000

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 Segment
Segment Reporting [Abstract]
Number of operating segment	1

Income Taxes - Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 0	$ 0
State	(2,000)	28,000
Foreign	0	(10,000)
Total current tax (expense) benefit	(2,000)	18,000
Deferred:
Federal	0	84,000
State	0	22,000
Foreign	0	0
Total deferred tax (expense) benefit	0	106,000
Total tax (expense) benefit	$ (2,000)	$ 124,000

Verdeca-BIOX Transactions

12 Months Ended

Dec. 31, 2021

Equity Method Investments And Joint Ventures [Abstract]

Verdeca-BIOX Transactions

Note 11. Verdeca-BIOX Transactions

In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

On November 12, 2020, the Company entered into a Master Transaction Agreement with BIOX pursuant to which (i) the Company sold all of its memberships interests it owned in Verdeca to BIOX, and (ii) the Company and BIOX entered into a license agreement for certain intellectual property rights, including rights to the Company’s HB4 soybean trait and its GoodWheat portfolio of specialty wheat products in South and Central America. Prior to the transaction, Verdeca was equally owned by the Company and a wholly-owned subsidiary of BIOX.

In consideration for the sale of the membership interests in Verdeca and entering into the license agreement, on November 12, 2020, BIOX paid the Company $5,000,000 in cash and issued the Company 1,875,000 shares of BIOX common stock. BIOX also paid the Company an additional $1,000,000 for transaction expenses and fees and is obligated to pay $2,000,000 in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of Haab 4 soybeans (“HB4”) or China approving the HB4 soybean trait for “food and feed”. In addition to the above payments, BIOX is also obligated to pay the Company quarterly royalty payments equal to six percent (6%) of the net revenues BIOX or its affiliates receive from HB4 soybean sales and twenty five percent (25%) of the net revenues BIOX or its affiliates receive from sales of licensed wheat products; provided that total royalty payments for HB4 soybeans shall not exceed $10,000,000. The total amount of fixed consideration agreed upon as of the date of the transaction was $16,968,750. The fixed consideration was allocated based on estimates of the stand-alone selling prices. A fixed consideration in the amount of $10,288,000, including $6,650,000 of corporate securities received, has been allocated to the sale of the membership interest in Verdeca and resulted in a gain of $8,814,000 recorded on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. Inventory with a carrying value of $1,474,000 was derecognized in connection with the sale of the membership interest in Verdeca. A fixed consideration in the amount of $6,680,000, including $4,318,000 of corporate securities received, has been allocated to the sale of intellectual property rights and has been recorded as license revenues on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. As of December 31, 2020, the Company had $800,000 recorded within accounts receivable on its consolidated balance sheets related to this transaction, which were collected during the year ended December 31, 2021, but no additional proceeds were received. Any future proceeds from the agreement will be allocated in the same proportion.

All of the shares of BIOX were sold in June 2021 and generated a one-time impact on liquidity in the amount of $22.2 million of gross proceeds. See Note 6.

Verdeca-BIOX Transactions - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Nov. 12, 2020	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Cash receivable from sale of interest in joint venture				$ 3,153,000
Gain on sale of membership interests in Verdeca				8,814,000
Inventory contributed			$ 4,433,000	3,812,000
Revenues			6,780,000	8,034,000
Corporate securities				4,318,000
Accounts receivable			1,370,000	1,406,000
Gross proceeds on sale		$ 22,200,000
License
Variable Interest Entity [Line Items]
Revenues			$ 17,000	6,801,000
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member]
Variable Interest Entity [Line Items]
Cash receivable from sale of interest in joint venture	$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture	1,875,000
Additional cash receivable for transaction expenses and fees	$ 1,000,000
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Sale of interest in joint venture, description of transaction			BIOX also paid the Company an additional $1,000,000 for transaction expenses and fees and is obligated to pay $2,000,000 in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of Haab 4 soybeans (“HB4”) or China approving the HB4 soybean trait for “food and feed”.
Percentage of royalty payments on net revenues	6.00%
Percentage of royalty payments on net revenues received from sales of licensed wheat products	25.00%
Sale of interest in joint venture, fixed consideration agreed amount	$ 16,968,750
Fixed consideration allocated to sale of membership interest	10,288,000
Corporate securities received allocated to sale of member ship interest	6,650,000
Gain on sale of membership interests in Verdeca				8,814,000
Inventory contributed				1,474,000
Accounts receivable				800,000
Proceeds from accounts receivable			$ 800,000
Additional proceeds received			$ 0
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member] \| License
Variable Interest Entity [Line Items]
Revenues				6,680,000
Corporate securities				$ 4,318,000
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member] \| Maximum [Member]
Variable Interest Entity [Line Items]
Technology royalty revenue receivable on trait fees, from sale of interest in joint venture	$ 10,000,000

Related Party Transactions - Additional Information (Detail)	1 Months Ended				3 Months Ended	12 Months Ended
	Feb. 01, 2022 USD ($)	Apr. 30, 2020 USD ($) a Lease	Mar. 31, 2020 USD ($) a	Feb. 28, 2019 USD ($) a	Mar. 31, 2020 USD ($) a	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Related Party Transaction [Line Items]
Royalty fees due						$ 64,000	$ 80,000
Number of lease amendments \| Lease		2
Lease payments						84,000	84,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land \| a				10
Operating leases, term of contract				2 years
Rent payments				$ 1,200
Out of pocket costs					$ 126,400
Payments received from contractor					$ 44,000
Mr. Kevin Comcowich [Member] \| Amendment [Member]
Related Party Transaction [Line Items]
Acres of land \| a		15	10		10
Operating leases, term of contract		2 years	2 years		2 years
Number of additional properties under lease agreement		two additional 15-acre parcels	two additional 10-acre parcels
Rent payments		$ 1,200	$ 1,200
Mr. Comcowich [Member] \| Subsequent Event [Member]
Related Party Transaction [Line Items]
Total compensation for service	$ 34,000
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due						$ 64,000	$ 80,000

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	889,759	661,701
Shares Subject to Outstanding, Options granted	1,227,042	502,494
Shares Subject to Outstanding, Options Forfeited	(440,166)	(174,508)
Shares Subject to Outstanding, Options Expired	(254,440)	(99,928)
Shares Subject to Outstanding, Ending Balance	1,422,195	889,759
Shares Subject to Outstanding, Vested and expected to vest	1,322,111
Shares Subject to Outstanding, Exercisable	743,109
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 14.46	$ 21.60
Weighted-Average Exercise Price Per Share, Options granted	2.76	4.28
Weighted-Average Exercise Price Per Share, Options forfeited	3.09	5.91
Weighted-Average Exercise Price Per Share, Options expired	29.02	25.56
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	5.28	$ 14.46
Weighted Average Exercise Price Per Share, Vested and expected to vest	5.47
Weighted Average Exercise Price Per Share, Exercisable	$ 7.54
Aggregate Intrinsic Value, Outstanding Balance		$ 240	$ 305
Aggregate Intrinsic Value, Options Forfeited	$ 1,086

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Summary of Revenues Based on Location of Customers

Revenues based on the location of the customers, are as follows (in thousands):


	Year Ended December 31,
	2021		2020
United States	$	6,003	$	761
Argentina		26		6,681
India		7		100
Africa		—		106
Canada		503		354
Spain		225		—
United Kingdom		16		—
Austria		—		32
Total	$	6,780	$	8,034

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Organization

Arcadia Biosciences, Inc. (the "Company"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in American Falls, Idaho, and Chatsworth, California. The Company was reincorporated in Delaware in March 2015.

The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The recent acquisition of the businesses of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) added bath and body care products, as well as coconut water, to the Company’s portfolio.

In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 8), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and Provault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand.

In April 2021, the newly formed Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”) acquired the physical and intellectual property assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The Company sold all of the assets and liabilities related to the subsidiary Arcadia Spain in November 2021 to a European buyer (the "buyer"), to focus on the US domestic market. The loss on sale of Arcadia Spain recorded on the consolidated statements of operations and comprehensive loss was $497,000. The buyer assumed all present and future liabilities, including the initial commitments related to the 2022 planting season.

In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 10) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. As a result, the Company recorded impairments of property and equipment in the amount of $1.4 million and $0 for the years ended December 31, 2021, and 2020, respectively. The Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, using prices for similar assets. See Note 5.

Liquidity, Capital Resources, and Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2021, the Company had an accumulated deficit of $226.5 million, and cash and cash equivalents of $28.7 million. For the years ended December 31, 2021 and 2020, the Company had net losses of $16.1 million and $6.0 million, respectively, and net cash used in operations of $25.9 million and $30.2 million, respectively. The Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If

the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Basis of Presentation and Principles of Consolidation

Use of Estimates

Cash and cash equivalents

Restricted cash

Investments in debt and equity securities

Other-than-temporary impairments on investments

Accounts receivable

Inventory

Zola Coconut water: Inventories mainly consist of coconut water imported from Thailand, freight-in, supplies, and labor.

Property and equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:


	Years
Laboratory equipment	5
Software and computer equipment	3
Machinery and equipment	2-20
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

* Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Impairment of long-lived intangible assets and goodwill

Intangible assets, net

Goodwill

Fair value of financial instruments

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 3 inputs are unobservable inputs for the asset or liability.

Concentration of risk

Customer concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):


	As of December 31,
	2021		2020
Customer B		11		21
Customer D		15		—
Customer C		—		12
Customer E		11		—
Customer A		—		57

Customers representing greater than 10% of total revenues were as follows (in percentages):


	For Year Ended December 31,
	2021		2020
Customer D		11		—
Customer B		10		7
Customer A		—		83

Stock-based compensation


	Year Ended December 31,
	2021		2020
	(in thousands)
Research and development	$	98	$	341
Selling, general and administrative		1,443		1,701
Total stock-based compensation	$	1,541	$	2,042

Income taxes

Net loss per share

Revenue recognition

The Company derives its revenues from product sales, licensing agreements, royalty fees, contract research agreements, and government grants.

Unearned revenue

Cost of product revenues

Research and development expenses

Change in fair value of contingent consideration

Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 17.

Change in the estimated fair value of common stock warrant liabilities

Change in the estimated fair value of common stock warrant liabilities is comprised of the fair value remeasurement of liability classified common stock warrants. See Note 15.

Product Revenues

Revenue recognition

Product revenues

recorded as revenues and included in cost of product revenues at the time the sale is recognized. Revenues fluctuate depending on the timing of shipments of product to our customers.

License revenues

Royalty revenues

Contract Research and Government Grant Revenues

Revenue recognition

Contract research and government grant revenues

Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Debt

Note 19. Debt

No maturities of current and noncurrent debt are due as of December 31, 2021. Maturities of current and noncurrent debt as of December 31, 2020 were $1.1 million, and $2.1 million, respectively.

Vehicle Loans

The Company entered into notes payable agreements to finance the purchase of company vehicles. During the year ended December 31, 2021, the Company paid all notes payable related to company vehicles in full.

Paycheck Protection Program Note

On April 16, 2020, the Company borrowed $1.1 million through MidFirst Bank, a federally chartered savings association (the "Lender"), and entered into a promissory note for the same amount under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. During 2021, the Company applied for full PPP loan forgiveness, and in August 2021, the lender notified Arcadia that the SBA had forgiven the original loan in full. During the year ended December 31, 2021, the amount forgiven has been recorded as gain on extinguishment of PPP loan on the consolidated statements of operations and comprehensive loss, as the Company has been legally released from being the primary obligor in accordance with ASC 405-20, Liabilities – Extinguishment of Liabilities.

Promissory Note

On June 26, 2020, the Company executed a promissory note (the “Note") in the amount of $2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $2.0 million. Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%. The Company was required to make monthly interest payments on the Note to the Lender and pay the full principal amount plus any accrued but unpaid interest outstanding under the Note no later than May 18, 2023. The Company and the Lender also entered into a Pledge and Security Agreement dated as of May 18, 2020 whereby the Company agreed to secure the Note by granting a security interest to the Lender for the Company’s deposit account held with and controlled by the Lender. On February 26, 2021, the Company repaid the full balance of $2.0 million, and on March 31, 2021, the line of credit was closed. As of December 31, 2021, there was no outstanding balance of the Note. Due to the lender’s control of the deposit account, a balance of $2.0 million was included in restricted cash on the consolidated balance sheets as of December 31, 2020.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss before income taxes are as follows (in thousands):


	Year Ended December 31,
	2021			2020
Domestic	$	(16,006	)	$	(6,150	)
Foreign		(126	)		—
Loss before income taxes	$	(16,132	)	$	(6,150	)

Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes


	Year Ended December 31,
	2021			2020
Current:
Federal	$	—		$	—
State		(2	)		28
Foreign		—			(10	)
Total current tax (expense) benefit		(2	)		18
Deferred:
Federal		—			84
State		—			22
Foreign		—			—
Total deferred tax (expense) benefit		—			106
Total tax (expense) benefit	$	(2	)	$	124

Reconciliation of the Statutory Federal Income Tax Rate

The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:


	Year Ended December 31,
	2021			2020
Expected income tax provision at the federal statutory rate		21.0	%		21.0	%
State taxes, net of federal benefits		(20.1	)%		9.4	%
Impact of section 382 study		(10.4	)%		—
Change in valuation allowance		(0.4	)%		(43.8	)%
Transaction costs		(1.0	)%		(2.2	)%
Derivative liabilities		11.7	%		22.4	%
Non-Controlling Interest		(1.9	)%		(4.7	)%
Gain on debt extinguishment		1.5	%		—
withholding taxes		—			(0.2	)%
Other		(0.4	)%		—
Income tax provision		—			1.9	%

Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):


	As of December 31,
	2021			2020
Deferred tax assets:
Net operating loss carryforwards	$	14,586		$	15,478
Unearned revenue		1			2
Stock-based compensation		3,677			3,881
Accrued payroll and benefits		3			236
Research and development credits		16			16
Fixed asset basis difference		73			84
Inventory reserve		422			491
Charitable contributions		2			3
Income from partnerships		163			—
Lease liability		752			1,622
Contingent consideration		456			531
Allowance for bad debt		27			—
Amortized intangibles		660			—
Goodwill		366			—
Total deferred tax assets		21,204			22,344
Deferred tax liabilities:
Right of use asset		(699	)		(1,548	)
Amortizable intangibles		—			(98	)
Income from partnerships		—			(13	)
Other		—			(174	)
Total deferred tax liabilities		(699	)		(1,833	)
Less valuation allowance		(20,505	)		(20,511	)
Net deferred tax assets	$	—		$	—

Schedule of Unrecognized Tax Benefits

As of December 31, 2021, the Company had the following unrecognized tax benefits (in thousands):


	Year Ended December 31,
	2021		2020
Unrecognized tax benefit beginning balance	$	17	$	—
Increases for tax positions taken in prior years		—		2
Decreases for tax positions taken in prior years		—		—
Increases for tax positions taken in current years		—		15
Settlements		—		—
Unrecognized tax benefit ending balance	$	17	$	17

Description of Business - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Accumulated deficit	$ (226,485,000)	$ (211,825,000)
Cash and cash equivalents	28,685,000	14,042,000
Net income (losses)	(16,134,000)	(6,026,000)
Net cash used in operations	(25,868,000)	(30,218,000)
Loss on sale of Arcadia Spain	497,000
Impairments of property and equipment	$ 1,400,000	$ 0

Summary of Significant Accounting Policies - Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,541	$ 2,042
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	98	341
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,443	$ 1,701

Related-Party Transactions

12 Months Ended

Dec. 31, 2021

Related-Party Transactions

Note 24. Related Party Transactions

The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors.

Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties. Outlined below are details of agreements between the Company and its related parties:

JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $64,000 and $80,000 as of December 31, 2021 and December 31, 2020, respectively, and are included in the consolidated balance sheets as amounts due to related parties.

The Company currently leases land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company has grown hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $1,200 per acre per year. During the quarter ended March 31, 2020, the Company engaged a third-party contractor to construct a fence on the property to adhere to the rules of the hemp pilot program. Out of pocket costs to build this fence were approximately $126,400. Mr. Comcowich supplied materials to the contractor and received payments from the contractor totaling approximately $44,000. In March and April 2020, the Company entered into two lease amendments for two additional 10-acre parcels and two additional 15-acre parcels, at the same lease rate of $1,200 per acre per year, and with a term of two years. The Company made lease payments in the amount of $84,000 and $84,000 for the years ended December 31, 2021 and 2020, respectively. Mr. Comcowich served as the Company's interim chief executive officer from January 1, 2022 to February 1, 2022, and received $34,000 in total compensation for his services in this role.

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):


	As of December 31,
	2021		2020
Accounts payable - trade	$	1,411	$	726
Payroll and benefits		1,606		1,489
Inventory		72		965
Research and development		—		45
Royalty fees due to unrelated parties		51		276
Consulting		79		153
Rent and utilities		127		78
Audit and tax fees		72		57
Legal		58		152
Other		162		164
Total accounts payable and accrued expenses	$	3,638	$	4,105

Intangible Assets, Net - Schedule of Intangible Assets, Net (Parenthetical) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 3,302,000	$ 0

Warrants - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	(30,000)
Warrants Outstanding	5,834,959	5,463,620
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.99
Warrants Outstanding	393,839
January 2021 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	2 years
Exercise Price Per Share	$ 3.08
Warrants Outstanding	7,500
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 3.00
Warrants Outstanding	2,618,658	2,618,658
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 3.82
Warrants Outstanding	130,933	130,933
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 3.85
Warrants Outstanding	641,416	641,416
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 4.97
Warrants Outstanding	32,071	32,071
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 4.78
Warrants Outstanding	1,392,345	1,392,345
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 6.13
Warrants Outstanding	69,617	69,617
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 2.50
Warrants Outstanding	18,350	18,350
February 12, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.71
Warrants Outstanding	150,000	150,000
February 3, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.91
Warrants Outstanding	10,000	10,000
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 9.48
Warrants Outstanding	65,942	65,942
August 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-08
Term	2 years
Exercise Price Per Share	$ 1.92
Warrants Exercised during the Year	(20,000)
Warrants Outstanding		20,000
July 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-07
Term	2 years
Exercise Price Per Share	$ 2.19
Warrants Exercised during the Year	(10,000)
Warrants Outstanding		10,000
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 6.29
Warrants Outstanding	74,479	74,479
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 6.18
Warrants Outstanding	145,154	145,154
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 12.57
Warrants Outstanding	69,617	69,617
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 41.56
Warrants Outstanding	15,038	15,038

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Arcadia Wellness [Member]	Industrial Seed Innovations [Member]	December 2020 Offering [Member]	January 2021 PIPE [Member]	June 2018 Warrants [Member]	May 2020 Warrants Transaction [Member]	May 2020 Warrants [Member]	March 2018 PIPE [Member]	July 2020 Warrants Transaction [Member]	July 2020 Warrants [Member]	Common Stock [Member]	Common Stock [Member] Arcadia Wellness [Member]	Common Stock [Member] Industrial Seed Innovations [Member]	Common Stock [Member] December 2020 Offering [Member]	Common Stock [Member] January 2021 PIPE [Member]	Common Stock [Member] June 2018 Warrants [Member]	Common Stock [Member] March 2018 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Arcadia Wellness [Member]	Additional Paid-In Capital [Member] Industrial Seed Innovations [Member]	Additional Paid-In Capital [Member] December 2020 Offering [Member]	Additional Paid-In Capital [Member] January 2021 PIPE [Member]	Additional Paid-In Capital [Member] June 2018 Warrants [Member]	Additional Paid-In Capital [Member] May 2020 Warrants Transaction [Member]	Additional Paid-In Capital [Member] May 2020 Warrants [Member]	Additional Paid-In Capital [Member] March 2018 PIPE [Member]	Additional Paid-In Capital [Member] July 2020 Warrants Transaction [Member]	Additional Paid-In Capital [Member] July 2020 Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2019	$ 8,325											$ 49							$ 214,826											$ (207,171)	$ 1	$ 620
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019												8,646,149
Issuance of shares related to employee stock purchase plan	51																		51
Issuance of shares related to employee stock purchase plan, Shares												19,667
Issuance of shares						$ 5,569			$ 2,444								$ 1	$ 1						$ 5,568			$ 2,443
Issuance of shares, Shares																	1,392,345	641,416
Issuance of investor warrants							$ 4,415			$ 2,059															$ 4,415			$ 2,059
Issuance of placement agent warrants				$ 287				$ 215			$ 101											$ 287				$ 215			$ 101
Issuance of common stock at closing of acquisition transaction			$ 432																		$ 432
Issuance of common stock at closing of acquisition transaction, Shares														132,626
Issuance of shares and warrants				8,000											$ 3							7,997
Issuance of shares and warrants, Shares															2,618,658
Offering costs				$ (939)																		$ (939)
Stock-based compensation	2,042																		2,042
Non-controlling interest contributions	1,578																															1,578
Unrealized losses on investment securities	(1)																														$ (1)
Net loss	(6,026)																													(4,655)		(1,371)
Stockholders Equity, Ending Balance at Dec. 31, 2020	28,552											$ 54							239,496											(211,825)		827
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2020												13,450,861
Issuance of shares related to employee stock purchase plan	38																		38
Issuance of shares related to employee stock purchase plan, Shares												15,189
Issuance of shares					$ 15,516											$ 8							$ 15,508
Issuance of shares, Shares																7,876,784
Issuance of placement agent warrants					942																		942
Issuance of common stock at closing of acquisition transaction		$ 2,053											$ 1							$ 2,052
Issuance of common stock at closing of acquisition transaction, Shares													827,401
Issuance of shares related to exercise of Service and Performance Warrants	22																		22
Issuance of shares related to exercise of Service and Performance Warrants, Shares												14,000
Offering costs					$ (2,084)																		$ (2,084)
Stock-based compensation	1,541																		1,541
Non-controlling interest contributions	750																															750
Net loss	(16,134)																													(14,660)		(1,474)
Stockholders Equity, Ending Balance at Dec. 31, 2021	$ 31,196											$ 63							$ 257,515											$ (226,485)		$ 103
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2021												22,184,235

Consolidated Joint Venture

12 Months Ended

Dec. 31, 2021

Equity Method Investments And Joint Ventures [Abstract]

Consolidated Joint Venture

Note 10. Consolidated Joint Venture

On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii.

Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of December 31, 2021, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $3,108,000 and $3,016,000, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal.

The Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $1,474,000 and $1,371,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2021 and 2020, respectively. Legacy’s equity interests are presented as non-controlling interests on the consolidated balance sheets. Refer to Note 2 for basis of presentation.

In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Retirement Benefits

12 Months Ended

Dec. 31, 2021

Compensation And Retirement Disclosure [Abstract]

Retirement Benefits

Note 21. Retirement Benefits

The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50% of the amount of the employee’s salary deduction, not to exceed 3% of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did not make discretionary matching contributions during the years ended December 31, 2021 and 2020.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Lessee Disclosure [Abstract]

Schedule of Leases


Leases	Classification	December 31, 2021		December 31, 2020
Assets
Operating lease assets	Right of use asset	$	3,081	$	5,826
Total leased assets		$	3,081	$	5,826
Liabilities
Current - Operating	Operating lease liability - current	$	1,074	$	717
Noncurrent - Operating	Operating lease liability - noncurrent		2,220		5,389
Total leased liabilities		$	3,294	$	6,106


Lease Cost	Classification	For the Year Ended December 31, 2021			For the Year Ended December 31, 2020
Operating lease cost	SG&A and R&D Expenses	$	1,352		$	1,042
Short term lease cost (1)	SG&A and R&D Expenses		133			305
Sublease income (2)	SG&A and R&D Expenses		(63	)		(45	)
Net lease cost		$	1,422		$	1,302

(1)

Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less.

(2)

Sublease income is recorded as a reduction to lease expense.


Lease Term and Discount Rate	December 31, 2021			December 31, 2020
Weighted-average remaining lease term (years)		2.7			5.0
Weighted-average discount rate		6	%		6	%

Schedule of Maturities of Operating Lease Liabilities

The maturities of the operating lease liabilities as of December 31, 2021 are as follows (in thousands):


Years Ending December 31,	Amounts
2022	$	1,217
2023		1,237
2024		973
2025		168
2026 and thereafter		—
Total operating lease payments	$	3,595
Less: imputed interest	$	301
Total current and noncurrent operating lease liabilities	$	3,294

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	12,932,206	8,090,039
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,422,195	889,759
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	11,510,011	7,200,280

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	21.00%	21.00%
State taxes, net of federal benefits	(20.10%)	9.40%
Impact of section 382 study	(10.40%)	0.00%
Change in valuation allowance	(0.40%)	(43.80%)
Transaction costs	(1.00%)	(2.20%)
Derivative liabilities	11.70%	22.40%
Non-Controlling Interest	(1.90%)	(4.70%)
Gain on debt extinguishment	1.50%	0.00%
Withholding taxes	0.00%	(0.20%)
Other	(0.40%)	0.00%
Income tax provision	0.00%	1.90%

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 14,586	$ 15,478
Unearned revenue	1	2
Stock-based compensation	3,677	3,881
Accrued payroll and benefits	3	236
Research and development credits	16	16
Fixed asset basis difference	73	84
Inventory reserve	422	491
Charitable contributions	2	3
Income from partnerships	163	0
Lease liability	752	1,622
Contingent consideration	456	531
Allowance for bad debt	27	0
Amortized intangibles	660	0
Goodwill	366	0
Total deferred tax assets	21,204	22,344
Deferred tax liabilities:
Right of use asset	(699)	(1,548)
Amortizable intangibles	0	(98)
Income from Partnerships	0	(13)
Other	0	(174)
Total deferred tax liabilities	(699)	(1,833)
Less valuation allowance	(20,505)	(20,511)
Net deferred tax assets	$ 0	$ 0

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Assets
Operating lease assets	$ 3,081	$ 5,826
Total leased assets	3,081	5,826
Liabilities
Current - Operating	1,074	717
Noncurrent - Operating	2,220	5,389
Total leased liabilities	3,294	6,106
Lease Cost
Net lease cost	$ 1,422	$ 1,302
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 8 months 12 days	5 years
Weighted-average discount rate	6.00%	6.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 1,352	$ 1,042
Sublease income	(63)	(45)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 133	$ 305

Warrants - Summary of Key Terms and Activity of Liability Classified Common Stock Warrants (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	(30,000)
Warrants Outstanding	5,834,959	5,463,620
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.13
Warrants Outstanding	3,938,392
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 7.52
Warrants Outstanding	659,414	659,414
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 5.00
Warrants Outstanding	435,830	435,830
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years 6 months
Exercise Price Per Share	$ 9.94
Warrants Exercised during the Year		1,392,345
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 10.73
Warrants Exercised during the Year		641,416
Warrants Outstanding	641,416	641,416
January 2021, September 2019, June 2019, June 2018 and March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year		2,033,761
Warrants Outstanding	5,675,052	1,736,660

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 months 21 days	6 years 5 months 23 days
Expected volatility	121.00%	134.00%
Risk-free interest rate	0.86%	1.01%

Equity Financing

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Equity Financing

Note 14. Equity Financing

Private Placements

In January 2021, the Company issued in a private placement offering (the “January 2021 Private Placement”) pursuant to a securities purchase agreement (“January 2021 Purchase Agreement”) (i) 7,876,784 shares of its common stock, and (ii) warrants to purchase up to 3,938,392 shares of common stock at an exercise price of $3.13 per share (the “January 2021 Warrants”) and raised total gross proceeds of $25.1 million. The January 2021 Warrants are exercisable at any time at the option of the holder and expire 5.5 years from the date of issuance. In connection with the January 2021 Private Placement, the Company granted to a placement agent warrants to purchase a total of 393,839 shares of Common Stock (the “January 2021 Placement Agent Warrants”) that have an
exercise price per share equal to $3.99 and a term of 5.5 years from the date of issuance.

The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature. The Company utilized a Black Scholes Merton model on January 28, 2021 with the following assumptions: volatility of 123.8 percent, stock price of $2.88 and risk-free rate of 0.5%. The estimated fair value of the common stock warrant liability was subsequently remeasured at December 31, 2021 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. See Note 6.

The January 2021 Placement Agent Warrants were issued for services performed by the placement agent as part of the January 2021 Private Placement and were treated as offering costs. The value of the January 2021 Placement Agent Warrants was determined to be $942,000 using the Black-Scholes Model assumptions detailed in Note 6. The Company incurred additional offering costs totaling $1.9 million that consist of direct incremental legal, advisory, accounting and filing fees relating to the January 2021 Private Placement. The offering costs, inclusive of the January 2021 Placement Agent Warrants, totaled $2.8 million and allocated to the common stock warrant liability and the common stock using their relative fair values. A total of $769,000 was allocated to the common

stock warrant liability and expensed and the remaining $2.0 million was allocated to the common stock and offset to additional paid in capital.

In March 2018, the Company issued in a private placement offering (the “March 2018 Private Placement”) pursuant to a securities purchase agreement (“March 2018 Purchase Agreement”) (i) 300,752 shares of its common stock and (ii) warrants to purchase up to 300,752 shares of common stock at an initial exercise price equal to $45.75 (the “March 2018 Warrants”) and raised total gross proceeds of $10.0 million. The March 2018 Warrants are exercisable at any time at the option of the holder and expire five years from the date of issuance. In connection with the March 2018 Private Placement, the Company granted to a placement agent warrants to purchase a total of 15,038 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $41.5625 and a term of five years from the date of issuance.

The number of shares of common stock and the number and exercise price of the March 2018 Warrants issued in the March 2018 Private Placement were subject to adjustments as provided in the March 2018 Purchase Agreement. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the purchasers was 1,201,634, the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $10.7258.

Registered Direct Offerings

On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“Shelf Registration Statement”). This shelf registration process allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $50 million. This registration statement expired on its three-year anniversary, June 8, 2021.

In December 2020, the Company entered into a securities purchase agreement (the “December 2020 Purchase Agreement”) pursuant to which it sold (i) 2,618,658 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 2,618,658 shares of its common stock (the “December 2020 Warrants”) in a private placement, for total gross proceeds of $8.0 million (the “December 2020 Registered Direct Offering”). The December 2020 Registered Direct Offering closed on December 22, 2020. The December 2020 Warrants have an exercise price of $3.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the December 2020 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 130,933 shares of common stock (“December 2020 Placement Agent Warrants”) that have an exercise price per share equal to $3.8188 and a term of five years. See Note 15.

In September 2019, the Company entered into a securities purchase agreement (the “September 2019 Purchase Agreement”) pursuant to which it sold (i) 1,318,828 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 659,414 shares of its common stock (the “September 2019 Warrants”) in a private placement, for total gross proceeds of $10.0 million (the “September 2019 Registered Direct Offering”). The September 2019 Registered Direct Offering closed on September 5, 2019. The September 2019 Warrants have an exercise price of $7.52 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the September 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 65,942 shares of common stock (“September 2019 Placement Agent Warrants”) that have an exercise price per share equal to $9.4781 and a term of five years.

In June 2019, the Company entered into a securities purchase agreement (the “June 2019 Purchase Agreement”) pursuant to which it sold (i) 1,489,575 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,489,575 shares of its common stock (the “June 2019 Warrants”) in a private placement, for total gross proceeds of $7.5 million (the “June 2019 Registered Direct Offering”). The June 2019 Registered Direct Offering closed on June 14, 2019. The June 2019 Warrants have an exercise price of $5.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 74,479 shares of common stock (“June 2019 Placement Agent Warrants”) that have an exercise price per share equal to $6.2938 and a term of five years.

In June 2018, the Company entered into a securities purchase agreement (the “June 2018 Purchase Agreement”) pursuant to which it sold (i) 1,392,345 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,392,345 shares of its common stock (the “June

2018 Warrants”) in a private placement, for total gross proceeds of $14.0 million (the “June 2018 Registered Direct Offering”). The June 2018 Registered Direct Offering closed on June 14, 2018. The June 2018 Warrants have an exercise price of $9.94 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2018 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $12.568 and a term of five years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic	$ (16,006)	$ (6,150)
Foreign	(126)	0
Loss before income taxes	$ (16,132)	$ (6,150)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefit beginning balance	$ 17
Increases for tax positions taken in prior years		$ 2
Increases for tax positions taken in current years		15
Unrecognized tax benefit ending balance	$ 17	$ 17

Industrial Seed Innovations Acquisition (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values

The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values.


	Purchase Price Allocation
Inventory	$	511
Intangible assets, net		400
Goodwill		408
Deferred tax liability		(107	)
Total consideration allocated	$	1,212

The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at December 31, 2021.


	Purchase Price Allocation
Inventory	$	840
Prepaid and other current assets		62
Fixed assets		308
Deposits		82
Customer list		360
Trade names and trademarks		2,900
Formulations		260
Goodwill		1,240
Total consideration allocated	$	6,052

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accounts payable - trade	$ 1,411	$ 726
Payroll and benefits	1,606	1,489
Inventory	72	965
Research and development		45
Royalty fees due to unrelated parties	51	276
Consulting	79	153
Rent and utilities	127	78
Audit and tax fees	72	57
Legal	58	152
Other	162	164
Total accounts payable and accrued expenses	$ 3,638	$ 4,105

Investments and Fair Value Instruments

12 Months Ended

Dec. 31, 2021

Investments And Fair Value Instruments [Abstract]

Investments and Fair Value Instruments

Note 6. Investments and Fair Value Instruments

Investments

The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized and realized gains and losses are recognized as other income in the consolidated statements of operations and comprehensive loss.

The Company classified its investments in corporate securities of Bioceres Crop Solutions Corp. (“BIOX”) as short-term investments. The Company recorded realized gains of $10.2 million for the year ended December 31, 2021, associated with the sale of these corporate securities in other income, net, in the consolidated statements of operations and comprehensive loss.

The following tables summarize the amortized cost and fair value of the investment securities portfolio at December 30, 2021 and December 31, 2020.


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2021
Cash equivalents:
Money market funds	$	26,842	$	—	$	—	$	26,842
Total Assets at Fair Value	$	26,842	$	—	$	—	$	26,842


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2020
Cash equivalents:
Money market funds	$	12,082	$	—	$	—	$	12,082
Short-term investments:
Corporate securities		10,969		656		—		11,625
Total Assets at Fair Value	$	23,051	$	656	$	—	$	23,707

The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2021.

Fair Value Measurement

The fair value of the investment securities at December 31, 2021 were as follows:


	Fair Value Measurements at December 31, 2021
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	26,842	$	—	$	—	$	26,842
Total Assets at Fair Value	$	26,842	$	—	$	—	$	26,842

The fair value of the investment securities at December 31, 2020 were as follows:


	Fair Value Measurements at December 31, 2020
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,082	$	—	$	—	$	12,082
Short-term investments:
Corporate securities		11,625		—		—		11,625
Total Assets at Fair Value	$	23,707	$	—	$	—	$	23,707

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2021 or 2020. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and notes payable. For accounts receivable, accounts payable, accrued liabilities, and notes payable the carrying amounts of these financial instruments as of December 31, 2021 and December 31, 2020 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value.

The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah acquisition, as described in Note 17, a contingent liability resulting from the Industrial Seed Innovations (“ISI”) acquisition, as described in Note 7 and 17, and common stock warrant liabilities related to the March 2018, the June 2019, the September 2019, and the January 2021 Offerings described in Note 15.

The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of December 31, 2021 and December 31, 2020, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The contingent liability related to the ISI acquisition was measured and recorded on a recurring basis as of December 31, 2021 and December 31, 2020, using unobservable inputs, namely ISI’s forecasted revenue. A significant deviation in ISI’s forecasted revenue could result in a significantly lower (higher) fair value measurement.

The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at December 31, 2021 and 2020:


	January 2021 Warrants					September 2019 Warrants						June 2019 Warrants						March 2018 Warrants
	December 31, 2021			December 31, 2020		December 31, 2021			December 31, 2020			December 31, 2021			December 31, 2020			December 31, 2021			December 31, 2020
Expected term (in years)		4.58			—		3.20			4.20			2.96			3.96			1.22			2.22
Expected volatility		129.8	%		—		109.7	%		135.0	%		110.8	%		135.0	%		86.0	%		130.0	%
Risk-free interest rate		1.2	%		—		0.9	%		0.3	%		0.8	%		0.3	%		0.5	%		0.1	%
Expected dividend yield		0	%		—		0	%		0	%		0	%		0	%		0	%		0	%

The significant unobservable input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement.

The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):


(Dollars in thousands)	Common Stock Warrant Liability - March 2018 Purchase Agreement			Common Stock Warrant Liability - June 2018 Offering			Common Stock Warrant Liability - June 2019 Offering			Common Stock Warrant Liability - September 2019 Offering			Common Stock Warrant Liability - January 2021 Offering			Contingent Liabilities			Total
Balance as of December 31, 2019	$	4,579		$	5,444		$	1,993		$	2,920		$	—		$	2,000		$	16,936
Change in fair value and other adjustments		(2,277	)		(1,426	)		(1,161	)		(1,706	)		—			—		$	(6,570	)
Exercise of warrants		(1,641	)		(4,018	)		—			—			—			—		$	(5,659	)
ISI acquisition contingent consideration		—			—			—			—			—			280		$	280
Balance as of December 31, 2020	$	661		$	—		$	832		$	1,214		$	—		$	2,280		$	4,987
Initial recognition		—			—			—			—		$	9,631			—		$	9,631
Change in fair value and other adjustments		(654	)		—			(662	)		(991	)		(6,638	)		(210	)	$	(9,155	)
Balance as of December 31, 2021	$	7		$	—		$	170		$	223		$	2,993		$	2,070		$	5,463

Consolidated Joint Venture - Additional Information (Detail)		12 Months Ended
	Aug. 09, 2019 Individual	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 1,474,000	$ 1,371,000
Archipelago Ventures Hawaii, LLC [Member] \| Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		50.75%
Capital contributions		$ 3,108,000
Archipelago Ventures Hawaii, LLC [Member] \| Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		49.25%
Capital contributions		$ 3,016,000

Industrial Seed Innovations Acquisition - Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 408,000
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Inventory	$ 511,000
Intangible assets, net	400,000
Goodwill	408,000
Deferred tax liability	(107,000)
Total consideration allocated	$ 1,212,000

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,950	$ 8,426
Less accumulated depreciation and amortization	(5,659)	(4,887)
Property and equipment, net	2,291	3,539
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,659	2,951
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	548	591
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,809	2,046
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	211	181
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	417	428
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,306	$ 2,229

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

The Company’s intangible assets, net as of December 31, 2021 and 2020, consist of the following:


	December 31, 2021						December 31, 2020
	Gross Carrying Amount		Accumulated Amortization and Impairment (1)		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Amortized intangible assets
Intellectual property	$	570	$	419	$	151	$	310	$	27	$	283
Customer lists		400		355		45		40		3		37
Total amortizable intangible assets	$	970	$	774	$	196	$	350	$	30	$	320

Indefinite-lived intangible assets
Brands and trademarks	$	2,950	$	2,662	$	288	$	50	$	—	$	50
Total intangible asset, net	$	3,920	$	3,436	$	484	$	400	$	30	$	370

Schedule of Future Amortization of Intellectual Property and Customer Lists

As of December 31, 2021, future amortization of intellectual property and customer lists is as follows:


Year Ending December 31,
2022	$	53
2023		53
2024		53
2025		4
2026		4
Thereafter		28
Total	$	196

Commitment and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 17. Commitments and Contingencies

Leases

The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 18.

Legal Matters

From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings.

Contingent Liability Related to the Anawah Acquisition

On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of December 31, 2021, the Company continues to pursue a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the consolidated balance sheet as an other noncurrent liability.

Contingent Liability Related to the ISI Acquisition

In August 2020, the Company acquired by merger Industrial Seed Innovations (ISI). A portion of the purchase price consideration for the acquisition in the amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration of $280,000 was measured and recorded at fair value. As of December 31, 2021, the full amount of the contingent consideration is included in other noncurrent liabilities as no installments will become due within 12 months from the consolidated balance sheets date. During the year ended December 31, 2021 as a result of a remeasurement of the contingent consideration, a $210,000 decrease in the related liability was recorded as a change in fair value of contingent consideration on the consolidated statements of operations and comprehensive loss.

Contracts

The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable.

The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due.

Royalties due to both related and unrelated parties accrued as of December 31, 2021 and 2020 were $115,000 and $356,000, respectively. Accrued royalties are included within accounts payable and accrued expenses on the consolidated balance sheets.

Milestone payments are contingent upon the successful development or implementation of various technologies. Payments for milestones yet to be achieved totaled $2.0 million for both the years ended December 31, 2021 and 2020, respectively. The timing of the payments is not determinable at this time pending research and development currently in progress; however, no payments were made during the years ended December 31, 2021 and 2020.

The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Collaborative Arrangements

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Arrangements

Note 13. Collaborative Arrangements

In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success.

The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development, which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Arcadia Wellness Acquisition

12 Months Ended

Dec. 31, 2021

Arcadia Wellness [Member]

Business Acquisition [Line Items]

Arcadia Wellness Acquisition

Note 8. Arcadia Wellness Acquisition

On May 17, 2021, the Company’s wholly owned subsidiary Arcadia Wellness, acquired the assets of Eko, Lief, and Zola. The acquisition included consumer brands of bath and body care products such as Soul Spring, the CBD-infused botanical therapy brand, Saavy Naturals, a line of natural body care products and Provault, a

CBD-infused sports performance formula. Also included in the purchase was Zola, a coconut water sourced from Thailand.

The acquisition was recorded as a business combination, in accordance with ASC Topic 805. The purchase price consideration for the acquisition totaled an estimated $6.1 million, of which $4.0 million in cash and $2.1 million in the form of 827,401 shares of the Company’s common stock, was paid during the month of May 2021. The cash consideration paid for the acquisition was funded by cash on hand.

Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the Arcadia Wellness acquisition of approximately $850,000 included in selling, general and administrative expenses in the Company's consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

The Company performed a preliminary allocation of purchase price as of the acquisition date based on management's estimates of fair value. The Company believes its estimates and assumptions are reasonable; however, the initial estimated purchase price allocation is subject to change as the Company finalizes its determination relating to the valuation of the assets acquired, finalization of key assumptions, approaches and judgments with respect to intangible assets acquired. Accordingly, future adjustments may impact the initial estimated amount of goodwill and other allocated amounts represented in the table below. The final determination of the fair value of the assets acquired will be completed as soon as the necessary information is available, but no later than one year from the acquisition date.

The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at December 31, 2021.


	Purchase Price Allocation
Inventory	$	840
Prepaid and other current assets		62
Fixed assets		308
Deposits		82
Customer list		360
Trade names and trademarks		2,900
Formulations		260
Goodwill		1,240
Total consideration allocated	$	6,052

The former shareholders of Eko, Lief, and Zola remain responsible for their pre-acquisition liabilities. In connection with the acquisition, the Company entered into a lease agreement for the use of offices, production equipment acquired, and storage warehouses. The lease was effective on May 17, 2021 and has a term of 3 years.

For the period from May 17 to December 31, 2021, the Company recognized approximately $4.3 million of revenue and $7.5 million of net loss relating to Arcadia Wellness, which included charges for the amortization and impairment of acquired intangible assets.

Acquired intangible assets of $3.5 million include trade names and trademarks of $2.9 million (indefinite useful life), customer list of $360,000 (fifteen-year useful life) and formulations of $260,000 (ten-year useful life).

The total weighted average amortization period for the acquired intangibles is 12.9 years.

The acquisition produced $1.2 million of goodwill. The goodwill is attributable to a combination of Arcadia Wellness’s expectation regarding a more meaningful engagement by the customers due to the scale of the combined Company, and other synergies. Goodwill will be tested for impairment at least annually (more frequently if certain indicators are present). Goodwill arising from the Arcadia Wellness acquisition is not deductible for tax purposes.

Supplemental Pro-Forma Results of Operations (Unaudited)

The following unaudited pro-forma condensed consolidated results of operations for the years ended December 31, 2021 and 2020, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2020 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding.


	For the year ended December 31,
	2021 (Pro forma)			2020 (Pro forma)
Total revenues	$	9,062		$	14,684
Net loss		(17,854	)		(8,152	)
Net loss attributable to common stockholders	$	(16,380	)	$	(6,781	)
Weighted average shares - Basic and diluted		21,590,895			10,786,418
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.76	)	$	(0.63	)

Industrial Seed Innovations Acquisition

12 Months Ended

Dec. 31, 2021

Industrial Seed Innovations [Member]

Business Acquisition [Line Items]

Industrial Seed Innovations Acquisition

Note 7. Industrial Seed Innovations Acquisition

In August 2020, the Company acquired by merger Industrial Seed Innovations (“ISI”), an Oregon-based industrial hemp breeding and seed company. As a result of the acquisition, the Company acquired ISI’s commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI’s Rogue, Umpqua and Santiam seed varieties are now part of Arcadia’s portfolio, alongside the Company’s GoodHemp line of hemp seeds.

The acquisition was recorded as a business combination, in accordance with ASC Topic 805. The purchase price consideration for the acquisition totaled an estimated $1,212,000, of which $500,000 in cash and $432,000, in the form of 132,626 shares of the Company’s common stock, was paid during the month of August 2020. The remaining amount of $280,000 was eligible to be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022, and is recorded as a contingent liability at fair value in the consolidated balance sheets as of December 31, 2021. A change in fair value of contingent consideration of $210,000 was recognized for the year ended December 31, 2021 as the annual revenue milestone was not met for this year. The cash consideration paid for the acquisition was funded by cash on hand.

Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the ISI acquisition of approximately $67,000 included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the year ended December 31, 2020.

The pro forma impact of the acquisition to the historical financial results was determined not to be significant.

The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values.


	Purchase Price Allocation
Inventory	$	511
Intangible assets, net		400
Goodwill		408
Deferred tax liability		(107	)
Total consideration allocated	$	1,212

A deferred tax liability arising from the difference between book purchase price allocation and tax basis has been assessed in the amount of $107,000. Deferred tax liabilities are required to be recorded in purchase accounting independently of whether the acquiror has a valuation allowance on its own net deferred tax assets. As a result, the combined entity now has additional deferred tax liabilities available to reduce the amount of valuation allowance necessary. Future reversals of existing taxable temporary differences are an objective source of future taxable income. Accordingly, the purchase accounting deferred tax liabilities enabled the realization of a portion of the existing deferred tax assets, thus allowing for a reduction in the valuation allowance. The reduction in the valuation allowance is not accounted for as part of the purchase accounting but is recognized in the consolidated statements of operations and comprehensive loss as a discrete tax benefit in the income tax provision.

The former shareholders of ISI remain responsible for ISI’s pre-acquisition liabilities. Pursuant to the acquisition agreement, the Company entered into a lease agreement with ISI for the use of land, equipment, greenhouses and buildings. The lease was effective upon the execution of the definitive acquisition agreement and had a term of 3 years with the option to renew for three additional 3-year terms. The lease was terminated effective December 31, 2021, as no further hemp seed production is deemed necessary as the inventory balance on hand is deemed sufficient.

Debt - Additional Information (Detail) - USD ($)	Feb. 26, 2021	Jun. 26, 2020	May 18, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 16, 2020
Debt Instrument [Line Items]
Debt - current				$ 0	$ 1,141,000
Debt - noncurrent				0	$ 2,105,000
Promissory Note [Member] \| Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 1,100,000
Promissory Notes [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			2.50%
Debt instrument maturity date			May 18, 2023
Debt instrument outstanding amount				0
Line of credit facility initiation date		Jun. 26, 2020
Line of credit facility maximum borrowing capacity		$ 2,000,000.0
Line of credit facility agreement date			May 18, 2020
Debt instrument interest rate terms			Pursuant to the Loan Agreement, the Note accrued interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Repayments of line of credit	$ 2,000,000.0
Promissory Notes [Member[ \| MidFirst Bank [Member] \| Restricted Cash [Member]
Debt Instrument [Line Items]
Deposit account				$ 2,000,000.0
Minimum [Member] \| Promissory Notes [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			3.25%
Maximum [Member] \| Promissory Notes [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity			$ 2,000,000.0

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Income Tax [Line Items]
Income tax (provision) benefit	$ (2,000)	$ 124,000
Increase (decrease) in net valuation allowance	$ (6,000,000)	$ 1,900,000
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years subject to examination to extent of NOLs being carried forward	2002
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2021
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2002
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 64,200,000
Operating loss carryforward	208,100,000
NOL deferred Tax asset	144,000.0
Operating loss carryforward expected to be unavailable	144,000.0
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 23,900,000

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in American Falls, Idaho, and Chatsworth, California. The Company was reincorporated in Delaware in March 2015. The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The recent acquisition of the businesses of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) added bath and body care products, as well as coconut water, to the Company’s portfolio. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 8), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and Provault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In April 2021, the newly formed Company’s wholly owned subsidiary Arcadia SPA, S.L. (“Arcadia Spain” or “ASPA”) acquired the physical and intellectual property assets of Agrasys S.A. (“Agrasys”), a food ingredients company based in Barcelona, Spain. The Company sold all of the assets and liabilities related to the subsidiary Arcadia Spain in November 2021 to a European buyer (the "buyer"), to focus on the US domestic market. The loss on sale of Arcadia Spain recorded on the consolidated statements of operations and comprehensive loss was $497,000. The buyer assumed all present and future liabilities, including the initial commitments related to the 2022 planting season. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 10) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. As a result, the Company recorded impairments of property and equipment in the amount of $1.4 million and $0 for the years ended December 31, 2021, and 2020, respectively. The Company assessed Archipelago’s fixed assets for impairment through an asset recoverability test, using prices for similar assets. See Note 5. Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2021, the Company had an accumulated deficit of $226.5 million, and cash and cash equivalents of $28.7 million. For the years ended December 31, 2021 and 2020, the Company had net losses of $16.1 million and $6.0 million, respectively, and net cash used in operations of $25.9 million and $30.2 million, respectively. The Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Stock-Based Compensation and Employee Stock Purchase Program

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation and Employee Stock Purchase Program

Note 16. Stock-Based Compensation and Employee Stock Purchase Program

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested.

In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. On May 17, 2021, upon completion of the Arcadia Wellness transaction, the Company granted 248,000 inducement stock option pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. On May 28, 2021, the Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of these inducement stock options. The inducement options grants have been issued outside of the 2015 Plan, but the options are subject to the terms and conditions of the 2015 Plan. As of December 31, 2021, a total of 1,596,209 shares of common stock were reserved for issuance under the 2015 Plan, of which 250,254 shares of common stock are available for future grant. As of

December 31, 2021, a total of 8,240 and 1,345,955 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2021 a total of 68,000 inducement options are outstanding.

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):


	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2019		661,701		$	21.60	$	305
Options granted		502,494			4.28		—
Options exercised		—			—		—
Options forfeited		(174,508	)		5.91		—
Options expired		(99,928	)		25.56		—
Outstanding — Balance at December 31, 2020		889,759			14.46	$	240
Options granted		1,227,042			2.76		—
Options exercised		—			—		—
Options forfeited		(440,166	)		3.09	$	1,086
Options expired		(254,440	)		29.02		—
Outstanding — Balance at December 31, 2021		1,422,195			5.28		—
Vested and expected to vest — December 31, 2021		1,322,111			5.47		—
Exercisable —December 31, 2021		743,109		$	7.54		—

Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercisable was $0 for both years ended December 31, 2021 and 2020.

As of December 31, 2021, there was $1.1 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 3.00 years.

On December 14, 2021, Matt Plavan provided notice to the Company of his resignation as Arcadia’s president, chief executive officer and director, effective as of December 31, 2021. On December 19, 2021, Arcadia and Mr. Plavan entered into a Separation and Release Agreement (the “Separation Agreement”) which provided that the vesting of all unvested options previously issued to Mr. Plavan accelerated pursuant to the terms of the Separation Agreement. In addition, the Separation Agreement extends the post-termination exercise period of the accelerated options from 90 days to up to two and one-half years. The stock compensation expense related to the modification of Mr. Plavan’s stock options was $154,000 and recognized in selling, general and administrative expenses during the year ended December 31, 2021.

In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Expected Term—The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.

Expected Volatility—The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards.

Risk-Free Interest Rate—The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.

Expected Dividend—The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders.

The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:


	Year Ended December 31,
Assumptions	2021			2020
Expected term (years)		6.31			6.48
Expected volatility		121	%		134	%
Risk-free interest rate		0.86	%		1.01	%
Expected dividend yield		—			—

The weighted-average, estimated grant date fair value of employee stock options granted during the years ended December 31, 2021 and 2020 was $2.41 and $3.80, respectively. The Company recognized $1.5 million and $2.0 million of compensation expense for stock options awards for the years ended December 31, 2021 and 2020, respectively.

Employee Stock Purchase Plan

The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2021, the number of shares of common stock reserved for future issuance under the ESPP is 111,722. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2021, 50,245 shares had been issued under the ESPP. The Company recorded $14,000 and $47,000 of ESPP related compensation expense for the years ended December 31, 2021 and 2020, respectively.

Recent Accounting Pronouncements - Additional Information (Detail)	Dec. 31, 2021
Accounting Standards Update 2019-12 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting Standards Update 2021-04 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

+ Details

- Definition

Date accounting standards update was adopted, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

+ Details

Industrial Seed Innovations Acquisition - Additional Information (Detail)	1 Months Ended		12 Months Ended
	Jan. 31, 2021 USD ($)	Aug. 31, 2020 USD ($) Installment shares	Dec. 31, 2021 USD ($) Installment Term shares
Business Acquisition [Line Items]
Change in fair value of contingent consideration			$ (210,000)
Lease option to extend, description			Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Maximum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract			5 years
Option to extend lease, term			6 years
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Purchase price consideration			$ 1,212,000
Cash paid for Acquisition			500,000
Business combination, equity interest issuable, value			432,000
Remaining amount paid in multiple installments		$ 280,000	280,000
Change in fair value of contingent consideration			(210,000)
Deferred tax liability			$ 107,000
Operating leases, term of contract			3 years
Existence of option to extend			true
Lease option to extend, description			The lease was effective upon the execution of the definitive acquisition agreement and had a term of 3 years with the option to renew for three additional 3-year terms. The lease was terminated effective December 31, 2021, as no further hemp seed production is deemed necessary as the inventory balance on hand is deemed sufficient.
Number of lease renewal term \| Term			3
Option to extend lease, term			3 years
Industrial Seed Innovations [Member] \| Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs	$ 67,000
Common Stock [Member] \| Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares \| shares			132,626
Number of annual installment of common stock shares payable \| Installment		2	2
Common Stock [Member] \| Industrial Seed Innovations [Member] \| Revenue Milestone in 2022 [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares		132,626	132,626

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets at Fair Value
Total Assets at Fair Value	$ 26,842	$ 23,707
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	26,842	12,082
Corporate Securities [Member]
Assets at Fair Value
Short-term investments		11,625
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	26,842	23,707
Level 1 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	$ 26,842	12,082
Level 1 [Member] \| Corporate Securities [Member]
Assets at Fair Value
Short-term investments		$ 11,625

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2021

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 12. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):


	As of December 31,
	2021		2020
Accounts payable - trade	$	1,411	$	726
Payroll and benefits		1,606		1,489
Inventory		72		965
Research and development		—		45
Royalty fees due to unrelated parties		51		276
Consulting		79		153
Rent and utilities		127		78
Audit and tax fees		72		57
Legal		58		152
Other		162		164
Total accounts payable and accrued expenses	$	3,638	$	4,105

Equity Financing - Additional Information (Detail)	1 Months Ended						12 Months Ended
Equity Financing - Additional Information (Detail)	Jan. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Jan. 28, 2021
Class Of Warrant Or Right [Line Items]
Offering costs allocated to common stock warrant liability and expensed \| $							$ 769,000
Registration statement expiration term							This registration statement expired on its three-year anniversary, June 8, 2021.
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance, aggregate offering prices \| $							$ 50,000,000
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued						1,201,634
Warrant issued, shares of common stock called by warrant						1,282,832
Warrants issued, exercise price \| $ / shares						$ 10.7258
December 2020 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		2,618,658
Proceeds from issuance of common stock and warrants gross \| $		$ 8,000,000.0
Offering closing period		Dec. 22, 2020
December 2020 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		2,618,658
Warrants issued, exercise price \| $ / shares		$ 3.00
Warrants expiration period		5 years 6 months
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued			1,318,828
Proceeds from issuance of common stock and warrants gross \| $			$ 10,000,000.0
Offering closing period			Sep. 05, 2019
September 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			659,414
Warrants issued, exercise price \| $ / shares			$ 7.52
Warrants expiration period			5 years 6 months
June 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued				1,489,575
Proceeds from issuance of common stock and warrants gross \| $				$ 7,500,000
Offering closing period				Jun. 14, 2019
June 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				1,489,575
Warrants issued, exercise price \| $ / shares				$ 5.00
Warrants expiration period				5 years 6 months
June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued					1,392,345
Proceeds from issuance of common stock and warrants gross \| $					$ 14,000,000.0
Offering closing period					Jun. 14, 2018
June 2018 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					1,392,345
Warrants issued, exercise price \| $ / shares					$ 9.94
Warrants expiration period					5 years 6 months
June 2018 Placement Agent Warrants [Member] \| June 2018 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					69,617
Warrants issued, exercise price \| $ / shares					$ 12.568
Warrant, exercisable term					5 years
June 2019 Placement Agent Warrants [Member] \| June 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				74,479
Warrants issued, exercise price \| $ / shares				$ 6.2938
Warrant, exercisable term				5 years
September 2019 Placement Agent Warrants [Member] \| September 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			65,942
Warrants issued, exercise price \| $ / shares			$ 9.4781
Warrant, exercisable term			5 years
December 2020 Placement Agent Warrants [Member] \| December 2020 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		130,933
Warrants issued, exercise price \| $ / shares		$ 3.8188
Warrant, exercisable term		5 years
March 2018 Private Placement [Member] \| March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued						300,752
Warrant issued, shares of common stock called by warrant						300,752
Warrants issued, exercise price \| $ / shares						$ 45.75
Warrants expiration period						5 years
Proceeds from issuance of common stock and warrants gross \| $						$ 10,000,000.0
March 2018 Private Placement [Member] \| March 2018 Placement Agent Warrants [Member] \| March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant						15,038
Warrants issued, exercise price \| $ / shares						$ 41.5625
Warrant, exercisable term						5 years
January 2021 Private Placement [Member] \| January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued	7,876,784
Warrant issued, shares of common stock called by warrant	3,938,392
Warrants issued, exercise price \| $ / shares	$ 3.13
Warrants expiration period	5 years 6 months
Proceeds from issuance of common stock and warrants gross \| $	$ 25,100,000
Remaining offering costs allocated to common stock and offset to additional paid in capital \| $	2,000,000.0
January 2021 Private Placement [Member] \| January 2021 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs allocated to common stock warrant liability and expensed \| $	$ 769,000
January 2021 Private Placement [Member] \| January 2021 Purchase Agreement [Member] \| Warrants [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								123.8
January 2021 Private Placement [Member] \| January 2021 Purchase Agreement [Member] \| Warrants [Member] \| Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								2.88
January 2021 Private Placement [Member] \| January 2021 Purchase Agreement [Member] \| Warrants [Member] \| Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input								0.5
January 2021 Private Placement [Member] \| January 2021 Placement Agent Warrants [Member] \| January 2021 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant	393,839
Warrants issued, exercise price \| $ / shares	$ 3.99
Warrant, exercisable term	5 years 6 months
Issuance of placement agent warrants \| $	$ 942,000
Offering costs \| $	1,900,000
January 2021 Private Placement [Member] \| January 2021 Placement Agent Warrants [Member] \| January 2021 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs \| $	$ 2,800,000

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Depreciation expense	$ 929,000	$ 632,000
Property and equipment, gross	7,950,000	8,426,000
Impairments of property and equipment	1,534,000	0
Write-down of intangible assets	1,400,000	0
Additional fixed assets impairment	100,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 267,000	$ 239,000

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 4,987	$ 16,936
Initial recognition	9,631
Change in fair value and other adjustments	(9,155)	(6,570)
Exercise of warrants		(5,659)
ISI acquisition contingent consideration		280
Ending Balance	5,463	4,987
Common Stock Warrant Liability [Member] \| Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	661	4,579
Change in fair value and other adjustments	(654)	(2,277)
Exercise of warrants		(1,641)
Ending Balance	7	661
Common Stock Warrant Liability [Member] \| June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance		5,444
Change in fair value and other adjustments		(1,426)
Exercise of warrants		(4,018)
Common Stock Warrant Liability [Member] \| June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	832	1,993
Change in fair value and other adjustments	(662)	(1,161)
Ending Balance	170	832
Common Stock Warrant Liability [Member] \| September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,214	2,920
Change in fair value and other adjustments	(991)	(1,706)
Ending Balance	223	1,214
Common Stock Warrant Liability [Member] \| January 2021 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Initial recognition	9,631
Change in fair value and other adjustments	(6,638)
Ending Balance	2,993
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,280	2,000
Change in fair value and other adjustments	(210)
ISI acquisition contingent consideration		280
Ending Balance	$ 2,070	$ 2,280

Intangible Assets, Net - Schedule of Future Amortization of Intellectual Property and Customer Lists (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
2022	$ 53
2023	53
2024	53
2025	4
2026	4
Thereafter	28
Finite-Lived Intangible Assets, Net, Total	$ 196	$ 320

Inventory (Tables)

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories, net consist of the following (in thousands):


	December 31, 2021		December 31, 2020
Raw materials	$	1,851	$	966
Goods in process		842		1,921
Finished goods		4,234		4,410
Inventories	$	6,927	$	7,297

Segment Reporting

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segment and Geographic Information

Note 22. Segment and Geographic Information

Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker.

Revenues based on the location of the customers, are as follows (in thousands):


	Year Ended December 31,
	2021		2020
United States	$	6,003	$	761
Argentina		26		6,681
India		7		100
Africa		—		106
Canada		503		354
Spain		225		—
United Kingdom		16		—
Austria		—		32
Total	$	6,780	$	8,034

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Summary of Warrants Issued to Purchase Common Stock


	Issuance Date	Term	Exercise Price Per Share		Warrants Exercised during the Year Ended December 31, 2020		Warrants Outstanding at December 31, 2020		Warrants Exercised during the Year Ended December 31, 2021			Warrants Outstanding at December 31, 2021
January 2021 Placement Agent Warrants	January 2021	5.5 years	$	3.99		—		—		—			393,839
January 2021 Service and Performance Warrants	January 2021	2 years	$	3.08		—		—		—			7,500
December 2020 Warrants	December 2020	5.5 years	$	3.00		—		2,618,658		—			2,618,658
December 2020 Placement Agent Warrants	December 2020	5 years	$	3.82		—		130,933		—			130,933
July 2020 Warrants	July 2020	5.5 years	$	3.85		—		641,416		—			641,416
July 2020 Placement Agent Warrants	July 2020	5.5 years	$	4.97		—		32,071		—			32,071
May 2020 Warrants	May 2020	5 years	$	4.78		—		1,392,345		—			1,392,345
May 2020 Placement Agent Warrants	May 2020	5 years	$	6.13		—		69,617		—			69,617
March 2020 Service and Performance Warrants	March 2020	3 years	$	2.50		—		18,350		—			18,350
February 12, 2020 Service and Performance Warrants	February 2020	2 years	$	4.71		—		150,000		—			150,000
February 3, 2020 Service and Performance Warrants	February 2020	2 years	$	4.91		—		10,000		—			10,000
September 2019 Placement Agent Warrants	September 2019	5 years	$	9.48		—		65,942		—			65,942
August 2019 Service and Performance Warrants	August 2019	2 years	$	1.92		—		20,000		(20,000	)		—
July 2019 Service and Performance Warrants	July 2019	2 years	$	2.19		—		10,000		(10,000	)		—
June 2019 Placement Agent Warrants	June 2019	5 years	$	6.29		—		74,479		—			74,479
April 2019 Service and Performance Warrants	April 2019	5 years	$	6.18		—		145,154		—			145,154
June 2018 Placement Agent Warrants	June 2018	5 years	$	12.57		—		69,617		—			69,617
March 2018 Placement Agent Warrants	March 2018	5 years	$	41.56		—		15,038		—			15,038
Total						—		5,463,620		(30,000	)		5,834,959

Summary of Key Terms and Activity of Liability Classified Common Stock Warrants

The key terms and activity of the liability classified common stock warrants are summarized as follows:


	Issuance Date	Term	Exercise Price Per Share		Warrants Exercised during the Year Ended December 31, 2020		Warrants Outstanding at December 31, 2020		Warrants Exercised during the Year Ended December 31, 2021		Warrants Outstanding at December 31, 2021
January 2021 Warrants	January 2021	5.5 years	$	3.13		—		—		—		3,938,392
September 2019 Warrants	September 2019	5.5 years	$	7.52		—		659,414		—		659,414
June 2019 Warrants	June 2019	5.5 years	$	5.00		—		435,830		—		435,830
June 2018 Warrants	June 2018	5.5 years	$	9.94		1,392,345		—		—		—
March 2018 Warrants	March 2018	5 years	$	10.73		641,416		641,416		—		641,416
Total						2,033,761		1,736,660		—		5,675,052

Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

Note 25. Subsequent Events

The Company has reviewed and evaluated subsequent events occurred after December 31, 2021 through the date the consolidated financial statements were available to be issued.

Arcadia Wellness Acquisition (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values

The following table presents the allocation of the purchase price of ISI assets acquired, based on their fair values.


	Purchase Price Allocation
Inventory	$	511
Intangible assets, net		400
Goodwill		408
Deferred tax liability		(107	)
Total consideration allocated	$	1,212

The following table presents the allocation of the purchase price of the assets acquired, based on their fair values at December 31, 2021.


	Purchase Price Allocation
Inventory	$	840
Prepaid and other current assets		62
Fixed assets		308
Deposits		82
Customer list		360
Trade names and trademarks		2,900
Formulations		260
Goodwill		1,240
Total consideration allocated	$	6,052

Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations


	For the year ended December 31,
	2021 (Pro forma)			2020 (Pro forma)
Total revenues	$	9,062		$	14,684
Net loss		(17,854	)		(8,152	)
Net loss attributable to common stockholders	$	(16,380	)	$	(6,781	)
Weighted average shares - Basic and diluted		21,590,895			10,786,418
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.76	)	$	(0.63	)

Recent Accounting Pronouncements

12 Months Ended

Dec. 31, 2021

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

Note 3. Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief, in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on the consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying other areas of existing guidance. The amendments are effective for all entities for fiscal years beginning after December 15, 2020. The Company adopted ASU No. 2019-12 on January 1, 2021 with an immaterial impact on the Company’s disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). The FASB Board is issuing this Update to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, the FASB Board focused on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The amendments in this Update are effective for public business entities that meet the definition of a smaller reporting company, as defined by the SEC, for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU No. 2020-06 on January 1, 2022, using the modified retrospective method. The main impact on the consolidated financial statements that will be prepared on Form 10-Q as of March 31, 2022, will be the reclassification of the Company's stock warrant liabilities to equity on the consolidated balance sheets, and the elimination of quarterly changes in the fair value of our stock warrant liabilities on the consolidated statement of operations and comprehensive loss.

In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in this Update clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted ASU No. 2021-04 on January 1, 2022 with an immaterial impact on the Company’s disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)						1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 19, 2021	Dec. 14, 2021	May 17, 2021 shares	May 20, 2015 shares	May 14, 2015	Jun. 30, 2019 shares	Sep. 30, 2018	Dec. 31, 2021 USD ($) IncentivePlan $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan								2
Shares Subject to Outstanding, Options granted								1,227,042	502,494
Total number of options outstanding								1,422,195	889,759	661,701
Intrinsic value of options exercisable \| $								$ 0	$ 0
Unrecognized compensation cost related to unvested stock-based compensation grants \| $								$ 1,100,000
Weighted-average remaining recognition period								3 years
Stock-based compensation \| $								$ 1,541,000	$ 2,042,000
Weighted-average estimated grant-date fair value of stock options granted \| $ / shares								$ 2.41	$ 3.80
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan								111,722
Stock-based compensation \| $								$ 14,000	$ 47,000
Percentage in payroll deductions to acquire shares of common stock					15.00%
Purchase plan offering period					6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage					85.00%
Issuance of common stock pursuant to employee stock purchase plan								50,245
First offering period, start date					May 14, 2015
First offering period, end date					Feb. 01, 2016
Separation Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period	2 years 6 months	90 days
Separation Agreement [Member] \| Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation \| $								$ 154,000
Inducement Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding, Options granted			248,000
Total number of options outstanding								68,000
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan								The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan				154,387				1,596,209
Options vesting period				4 years			2 years
Additional shares authorized for issuance under the plan						120,000
Common stock available for future grant								250,254
Total number of options outstanding								1,345,955
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan				10,637
Total number of options outstanding								8,240
Maximum [Member] \| 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period				10 years